175

References

176

References

R R

177

References

R R

1. Griffith, F. L.; Petrie, W. M. F. Hieratic Papyri from Kahun and Gurob:(principally of the Middle Kingdom). B. Quaritch: 1898.

2. Brown, A. C.; Fraser, T. R. On the Connection between Chemical Constitution and Physio-logical Action; with special reference to the Physiological Action of the Salts of the Am-monium Bases derived from Strychnia, Brucia, Thebaia, Codeia, Morphia, and Nicotia. J Anat Physiol 1868, 2, 224-242.

3. Langley, J. N. On the physiology of the salivary secretion. Part II. On the mutual antagonism of atropin and pilocarpin, having especial ref-erence to their relations in the sub-maxillary gland of the cat. J Physiol 1878, 1, 339-369.

4. Birdsall, N. J.; Hulme, E. C. Biochemical studies on muscarinic acetylcholine receptors. J Neu-rochem 1976, 27, 7-16.

5. Ehrlich, P. Address in Pathology on Chemo-therapeutics:: scientific principles, methods, and results. Lancet 1913, 182, 445-451.

6. Fischer, E. Einfluss der Configuration auf die Wirkung der Enzyme. Ber Dtsch Chem Ges 1894, 27, 2985-2993.

7. Ehrlich, P. Croonian lecture: on immunity with special reference to cell life. Proc R Soc 1899, 66, 424-448.

8. de Kloe, G. E.; Bailey, D.; Leurs, R.; de Esch, I. J. Transforming fragments into candidates: small becomes big in medicinal chemistry. Drug Dis-cov Today 2009, 14, 630-646.

9. de Graaf, C.; Vischer, H. F.; de Kloe, G. E.; Koo-istra, A. J.; Nijmeijer, S.; Kuijer, M.; Verheij, M. H.; England, P. J.; van Muijlwijk-Koezen, J. E.; Leurs, R.; de Esch, I. J. Small and colorful stones make beautiful mosaics: fragment-based che-mogenomics. Drug Discov Today 2013, 18, 323-330.

10. Keseru, G. M.; Makara, G. M. Hit discovery and hit-to-lead approaches. Drug Discov Today 2006, 11, 741-748.

11. Li, A. P. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov Today 2001, 6, 357-366.

12. Tanimoto, T.; Tsubokura, M.; Mori, J.; Pietrek, M.; Ono, S.; Kami, M. Differences in drug ap-proval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin. Invest New Drugs 2013, 31, 473-478.

13. Fujita, T.; Iwasa, J.; Hansch, C. QSAR and Strat-egies in the Design of Bioactive Compounds.

JK Seydel, Ed 1964, 207-218.14. W Adamson, G.; M Bird, J.; Palmer, G.; A Warr,

W. In-house chemical databases at Imperial Chemical Industries. J Mol Graphics 1986, 4, 165-169.

15. Swaan, P. W.; Ekins, S. Reengineering the phar-maceutical industry by crash-testing mole-cules. Drug Discov Today 2005, 10, 1191-1200.

16. Kubinyi, H. Structure-based design of enzyme inhibitors and receptor ligands. Curr Opin Drug Discov Devel 1998, 1, 4-15.

17. Wlodawer, A.; Vondrasek, J. Inhibitors of HIV-1 protease: a major success of structure-assist-ed drug design. Annu Rev Biophys Biomol Struct 1998, 27, 249-284.

18. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting can-cer with small molecule kinase inhibitors. Nat Rev Cancer 2009, 9, 28-39.

19. van Westen, G. J.; Wegner, J. K.; IJzerman, A. P.; van Vlijmen, H. W.; Bender, A. Proteochem-ometric modeling as a tool to design selective compounds and for extrapolating to novel tar-gets. Med Chem Commun 2011, 2, 16-30.

20. Lyne, P. D. Structure-based virtual screening: an overview. Drug Discov Today 2002, 7, 1047-1055.

21. Jacoby, E.; Boettcher, A.; Mayr, L.; Brown, N.; Jenkins, J. Chemogenomics: methods and appli-cations. Humana Press: New York, 2009.

22. Harris, C. J.; Stevens, A. P. Chemogenomics: structuring the drug discovery process to gene families. Drug Discov Today 2006, 11, 880-888.

23. Bajorath, J. Integration of virtual and high-throughput screening. Nat Rev Drug Dis-cov 2002, 1, 882-894.

24. Tanrikulu, Y.; Kruger, B.; Proschak, E. The holis-tic integration of virtual screening in drug dis-covery. Drug Discov Today 2013, 18, 358-364.

25. Leach, A. R.; Shoichet, B. K.; Peishoff, C. E. Pre-diction of protein-ligand interactions. Docking and scoring: successes and gaps. J Med Chem 2006, 49, 5851-5855.

26. Schultes, S.; Nijmeijer, S.; Engelhardt, H.; Kooistra, A. J.; Vischer, H. F.; de Esch, I. J. P.; Haaksma, E. J.; Leurs, R.; de Graaf, C. Mapping histamine H4 receptor-ligand binding modes. Med Chem Commun 2013, 4, 193-204.

27. Istyastono, E. P.; Nijmeijer, S.; Lim, H. D.; van de Stolpe, A.; Roumen, L.; Kooistra, A. J.; Vischer, H. F.; de Esch, I. J.; Leurs, R.; de Graaf, C. Molecular determinants of ligand binding

178

References

R R

modes in the histamine H(4) receptor: linking ligand-based three-dimensional quantitative structure-activity relationship (3D-QSAR) models to in silico guided receptor mutagen-esis studies. J Med Chem 2011, 54, 8136-8147.

28. Reddy, A. S.; Pati, S. P.; Kumar, P. P.; Pradeep, H. N.; Sastry, G. N. Virtual screening in drug discovery -- a computational perspective. Curr Protein Pept Sci 2007, 8, 329-351.

29. Rogers, D.; Hahn, M. Extended-connectivity fingerprints. J Chem Inf Model 2010, 50, 742-754.

30. Kooistra, A. J.; Binsl, T. W.; van Beek, J. H.; de Graaf, C.; Heringa, J. Electron density fin-gerprints (EDprints): virtual screening using assembled information of electron density. J Chem Inf Model 2010, 50, 1772-1780.

31. Sanders, M. P.; McGuire, R.; Roumen, L.; de Esch, I. J.; de Vlieg, J.; Klomp, J. P.; de Graaf, C. From the protein's perspective: the bene-fits and challenges of protein structure-based pharmacophore modeling. Med. Chem. Comm. 2012, 3, 28-38.

32. Güner, O. F. Pharmacophore perception, de-velopment, and use in drug design. Internation-al University Line, La Jolla, CA 2000, 29.

33. de Esch, I. J.; Timmerman, H.; Menge, W. M.; Nederkoorn, P. H. A qualitative model for the histamine H3 receptor explaining agonistic and antagonistic activity simultaneously. Arch Pharm (Weinheim) 2000, 333, 254-260.

34. Sanders, M. P.; Verhoeven, S.; de Graaf, C.; Rou-men, L.; Vroling, B.; Nabuurs, S. B.; de Vlieg, J.; Klomp, J. P. Snooker: a structure-based phar-macophore generation tool applied to class A GPCRs. J Chem Inf Model 2011, 51, 2277-2292.

35. ROCS, version 2.3.1; OpenEye Scientific Soft-ware: Santa Fe, NM.

36. Hawkins, P. C.; Skillman, A. G.; Nicholls, A. Comparison of shape-matching and docking as virtual screening tools. J Med Chem 2007, 50, 74-82.

37. Baroni, M.; Cruciani, G.; Sciabola, S.; Perruccio, F.; Mason, J. S. A common reference frame-work for analyzing/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application. J Chem Inf Model 2007, 47, 279-294.

38. Weininger, D.; Weininger, A.; Weininger, J. L. SMILES. 2. Algorithm for generation of unique SMILES notation. J Chem Inf Comput Sci 1989,

29, 97-101.39. Halgren, T. A. Merck molecular force field. I.

Basis, form, scope, parameterization, and per-formance of MMFF94. J Comp Chem 1996, 17, 490-519.

40. Pretsch, E.; Furst, A.; Badertscher, M.; Buergin, R.; Munk, M. E. C13Shift: a computer program for the prediction of carbon-13 NMR spectra based on an open set of additivity rules. J Chem Inf Comput Sci 1992, 32, 291-295.

41. Schaller, R. B.; Munk, M. E.; Pretsch, E. Spectra estimation for computer-aided structure de-termination. J Chem Inf Comput Sci 1996, 36, 239-243.

42. Huang, N.; Shoichet, B. K.; Irwin, J. J. Bench-marking sets for molecular docking. J Med Chem 2006, 49, 6789-6801.

43. Todeschini, R.; Consonni, V.; Xiang, H.; Holli-day, J.; Buscema, M.; Willett, P. Similarity co-efficients for binary chemoinformatics data: overview and extended comparison using simulated and real data sets. J Chem Inf Model 2012, 52, 2884-2901.

44. Kellenberger, E.; Foata, N.; Rognan, D. Ranking targets in structure-based virtual screening of three-dimensional protein libraries: methods and problems. J Chem Inf Model 2008, 48, 1014-1025.

45. Marcou, G.; Rognan, D. Optimizing fragment and scaffold docking by use of molecular inter-action fingerprints. J Chem Inf Model 2007, 47, 195-207.

46. Korb, O.; Stützle, T.; Exner, T. E. An ant colony optimization approach to flexible protein-li-gand docking. Swarm Intelligence 2007, 1, 115-134.

47. Jones, G.; Willett, P.; Glen, R. C. Molecular rec-ognition of receptor sites using a genetic algo-rithm with a description of desolvation. J Mol Biol 1995, 245, 43-53.

48. Goodsell, D. S.; Olson, A. J. Automated dock-ing of substrates to proteins by simulated an-nealing. Proteins 1990, 8, 195-202.

49. Abagyan, R.; Totrov, M.; Kuznetsov, D. ICM—a new method for protein modeling and design: applications to docking and structure predic-tion from the distorted native conformation. J Comp Chem 1994, 15, 488-506.

50. Huang, S. Y.; Grinter, S. Z.; Zou, X. Scoring functions and their evaluation methods for protein-ligand docking: recent advances and

179

References

R R

future directions. Phys Chem Chem Phys 2010, 12, 12899-12908.

51. Deng, Z.; Chuaqui, C.; Singh, J. Structural in-teraction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. J Med Chem 2004, 47, 337-344.

52. Desaphy, J.; Raimbaud, E.; Ducrot, P.; Rog-nan, D. Encoding protein-ligand interaction patterns in fingerprints and graphs. J Chem Inf Model 2013, 53, 623-637.

53. Singh, J.; Deng, Z.; Narale, G.; Chuaqui, C. Structural interaction fingerprints: a new ap-proach to organizing, mining, analyzing, and designing protein-small molecule complexes. Chem Biol Drug Des 2006, 67, 5-12.

54. Gaulton, A.; Bellis, L. J.; Bento, A. P.; Cham-bers, J.; Davies, M.; Hersey, A.; Light, Y.; Mc-Glinchey, S.; Michalovich, D.; Al-Lazikani, B.; Overington, J. P. ChEMBL: a large-scale bioac-tivity database for drug discovery. Nucleic Acids Res 2012, 40, D1100-1107.

55. Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wis-hart, D. S. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 2011, 39, D1035-1041.

56. Wiener, A.; Shudler, M.; Levit, A.; Niv, M. Y. Bit-terDB: a database of bitter compounds. Nucleic Acids Res 2012, 40, D413-419.

57. Liu, T.; Lin, Y.; Wen, X.; Jorissen, R. N.; Gilson, M. K. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 2007, 35, D198-201.

58. Mestres, J.; Gregori-Puigjane, E.; Valverde, S.; Sole, R. V. Data completeness--the Achilles heel of drug-target networks. Nat Biotechnol 2008, 26, 983-984.

59. Kubinyi, H. 3D Qsar in Drug Design: Volume 1: Theory Methods and Applications. Springer: 1993; Vol. 1.

60. Kubinyi, H. QSAR and 3D QSAR in drug design Part 2: applications and problems. Drug Discov Today 1997, 2, 538-546.

61. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J.; Meyer, E. F., Jr.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The Protein Data Bank: a computer-based archival file for macromolecular structures. J Mol Biol

1977, 112, 535-542.62. Isberg, V.; Vroling, B.; van der Kant, R.; Li, K.;

Vriend, G.; Gloriam, D. GPCRDB: an informa-tion system for G protein-coupled receptors. Nucleic Acids Res 2014, 42, D422-425.

63. Horn, F.; Weare, J.; Beukers, M. W.; Horsch, S.; Bairoch, A.; Chen, W.; Edvardsen, O.; Cam-pagne, F.; Vriend, G. GPCRDB: an information system for G protein-coupled receptors. Nu-cleic Acids Res 1998, 26, 275-279.

64. UniProt, C. Activities at the Universal Protein Resource (UniProt). Nucleic Acids Res 2014, 42, 7486.

65. Wishart, D. S.; Jewison, T.; Guo, A. C.; Wilson, M.; Knox, C.; Liu, Y.; Djoumbou, Y.; Mandal, R.; Aziat, F.; Dong, E.; Bouatra, S.; Sinelnikov, I.; Arndt, D.; Xia, J.; Liu, P.; Yallou, F.; Bjorndahl, T.; Perez-Pineiro, R.; Eisner, R.; Allen, F.; Neveu, V.; Greiner, R.; Scalbert, A. HMDB 3.0--The Human Metabolome Database in 2013. Nucleic Acids Res 2013, 41, D801-807.

66. Irwin, J. J.; Shoichet, B. K. ZINC--a free data-base of commercially available compounds for virtual screening. J Chem Inf Model 2005, 45, 177-182.

67. Irwin, J. J.; Sterling, T.; Mysinger, M. M.; Bols-tad, E. S.; Coleman, R. G. ZINC: a free tool to discover chemistry for biology. J Chem Inf Mod-el 2012, 52, 1757-1768.

68. Mysinger, M. M.; Carchia, M.; Irwin, J. J.; Shoichet, B. K. Directory of useful decoys, en-hanced (DUD-E): better ligands and decoys for better benchmarking. J Med Chem 2012, 55, 6582-6594.

69. Dong, X.; Han, S.; Zylka, M. J.; Simon, M. I.; Anderson, D. J. A diverse family of GPCRs ex-pressed in specific subsets of nociceptive sen-sory neurons. Cell 2001, 106, 619-632.

70. Kolakowski, L. F., Jr. GCRDb: a G-protein-cou-pled receptor database. Receptors Channels 1994, 2, 1-7.

71. Fredriksson, R.; Lagerstrom, M. C.; Lundin, L. G.; Schioth, H. B. The G-protein-coupled re-ceptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 2003, 63, 1256-1272.

72. Surgand, J. S.; Rodrigo, J.; Kellenberger, E.; Rognan, D. A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins 2006,

180

References

R R

62, 509-538.73. Venkatakrishnan, A. J.; Deupi, X.; Lebon, G.;

Tate, C. G.; Schertler, G. F.; Babu, M. M. Mo-lecular signatures of G-protein-coupled recep-tors. Nature 2013, 494, 185-194.

74. Deupi, X.; Kobilka, B. K. Energy landscapes as a tool to integrate GPCR structure, dynamics, and function. Physiology 2010, 25, 293-303.

75. Lambert, D. Drugs and receptors. Continuing Education in Anaesthesia, Critical Care & Pain 2004, 4, 181-184.

76. Gurevich, V. V.; Gurevich, E. V. Structural de-terminants of arrestin functions. Prog Mol Biol Transl Sci 2013, 118, 57-92.

77. Lohse, M. J.; Benovic, J. L.; Codina, J.; Caron, M. G.; Lefkowitz, R. J. Beta-arrestin: a protein that regulates beta-adrenergic receptor func-tion. Science 1990, 248, 1547-1550.

78. Urban, J. D.; Clarke, W. P.; von Zastrow, M.; Nichols, D. E.; Kobilka, B.; Weinstein, H.; Javitch, J. A.; Roth, B. L.; Christopoulos, A.; Sexton, P. M.; Miller, K. J.; Spedding, M.; Mail-man, R. B. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007, 320, 1-13.

79. Garland, S. L. Are GPCRs still a source of new targets? J Biomol Screen 2013, 18, 947-966.

80. Hollenstein, K.; de Graaf, C.; Bortolato, A.; Wang, M. W.; Marshall, F. H.; Stevens, R. C. Insights into the structure of class B GPCRs. Trends Pharmacol Sci 2014, 35, 12-22.

81. Hollenstein, K.; Kean, J.; Bortolato, A.; Cheng, R. K.; Dore, A. S.; Jazayeri, A.; Cooke, R. M.; Weir, M.; Marshall, F. H. Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 2013, 499, 438-443.

82. Siu, F. Y.; He, M.; de Graaf, C.; Han, G. W.; Yang, D.; Zhang, Z.; Zhou, C.; Xu, Q.; Wacker, D.; Jo-seph, J. S.; Liu, W.; Lau, J.; Cherezov, V.; Ka-tritch, V.; Wang, M. W.; Stevens, R. C. Structure of the human glucagon class B G-protein-cou-pled receptor. Nature 2013, 499, 444-449.

83. Ballesteros, J. A.; Weinstein, H. Integrated methods for the construction of three-dimen-sional models and computational probing of structure-function relations of G protein-cou-pled receptors. Methods Neurosci 1995, 25, 366-428.

84. Wang, C.; Wu, H.; Katritch, V.; Han, G. W.; Huang, X. P.; Liu, W.; Siu, F. Y.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the

human smoothened receptor bound to an anti-tumour agent. Nature 2013, 497, 338-343.

85. Stevens, R. C.; Cherezov, V.; Katritch, V.; Abag-yan, R.; Kuhn, P.; Rosen, H.; Wuthrich, K. The GPCR Network: a large-scale collaboration to determine human GPCR structure and func-tion. Nat Rev Drug Discov 2013, 12, 25-34.

86. Henderson, R.; Baldwin, J. M.; Ceska, T. A.; Zemlin, F.; Beckmann, E.; Downing, K. H. Mod-el for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. J Mol Biol 1990, 213, 899-929.

87. Pebay-Peyroula, E.; Rummel, G.; Rosenbusch, J. P.; Landau, E. M. X-ray structure of bacteri-orhodopsin at 2.5 angstroms from microcrys-tals grown in lipidic cubic phases. Science 1997, 277, 1676-1681.

88. Wieland, K.; Laak, A. M.; Smit, M. J.; Kuhne, R.; Timmerman, H.; Leurs, R. Mutational analysis of the antagonist-binding site of the histamine H(1) receptor. J Biol Chem 1999, 274, 29994-30000.

89. ter Laak, A. M.; Timmerman, H.; Leurs, R.; Nederkoorn, P. H.; Smit, M. J.; Donne-Op den Kelder, G. M. Modelling and mutation studies on the histamine H1-receptor agonist binding site reveal different binding modes for H1-ag-onists: Asp116 (TM3) has a constitutive role in receptor stimulation. J Comput Aided Mol Des 1995, 9, 319-330.

90. Shimamura, T.; Shiroishi, M.; Weyand, S.; Tsu-jimoto, H.; Winter, G.; Katritch, V.; Abagyan, R.; Cherezov, V.; Liu, W.; Han, G. W.; Kobayashi, T.; Stevens, R. C.; Iwata, S. Structure of the human histamine H1 receptor complex with doxepin. Nature 2011, 475, 65-70.

91. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yama-moto, M.; Miyano, M. Crystal structure of rho-dopsin: A G protein-coupled receptor. Science 2000, 289, 739-745.

92. Filipek, S.; Teller, D. C.; Palczewski, K.; Sten-kamp, R. The crystallographic model of rho-dopsin and its use in studies of other G pro-tein-coupled receptors. Annu Rev Biophys Biomol Struct 2003, 32, 375-397.

93. Jacobson, K. A.; Costanzi, S. New insights for drug design from the X-ray crystallographic structures of G-protein-coupled receptors. Mol Pharmacol 2012, 82, 361-371.

181

References

R R

94. Egloff, P.; Hillenbrand, M.; Klenk, C.; Batyuk, A.; Heine, P.; Balada, S.; Schlinkmann, K. M.; Scott, D. J.; Schutz, M.; Pluckthun, A. Structure of signaling-competent neurotensin receptor 1 obtained by directed evolution in Escherichia coli. Proc Natl Acad Sci U S A 2014, 111, E655-662.

95. Kruse, A. C.; Ring, A. M.; Manglik, A.; Hu, J.; Hu, K.; Eitel, K.; Hubner, H.; Pardon, E.; Valant, C.; Sexton, P. M.; Christopoulos, A.; Felder, C. C.; Gmeiner, P.; Steyaert, J.; Weis, W. I.; Garcia, K. C.; Wess, J.; Kobilka, B. K. Activation and al-losteric modulation of a muscarinic acetylcho-line receptor. Nature 2013, 504, 101-106.

96. Wang, C.; Jiang, Y.; Ma, J.; Wu, H.; Wacker, D.; Katritch, V.; Han, G. W.; Liu, W.; Huang, X. P.; Vardy, E.; McCorvy, J. D.; Gao, X.; Zhou, X. E.; Melcher, K.; Zhang, C.; Bai, F.; Yang, H.; Yang, L.; Jiang, H.; Roth, B. L.; Cherezov, V.; Stevens, R. C.; Xu, H. E. Structural basis for molecular recognition at serotonin receptors. Science 2013, 340, 610-614.

97. Tan, Q.; Zhu, Y.; Li, J.; Chen, Z.; Han, G. W.; Ku-fareva, I.; Li, T.; Ma, L.; Fenalti, G.; Li, J.; Zhang, W.; Xie, X.; Yang, H.; Jiang, H.; Cherezov, V.; Liu, H.; Stevens, R. C.; Zhao, Q.; Wu, B. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 2013, 341, 1387-1390.

98. Zhang, J.; Zhang, K.; Gao, Z. G.; Paoletta, S.; Zhang, D.; Han, G. W.; Li, T.; Ma, L.; Zhang, W.; Muller, C. E.; Yang, H.; Jiang, H.; Cherezov, V.; Katritch, V.; Jacobson, K. A.; Stevens, R. C.; Wu, B.; Zhao, Q. Agonist-bound structure of the human P2Y12 receptor. Nature 2014, 509, 119-122.

99. Zhang, K.; Zhang, J.; Gao, Z. G.; Zhang, D.; Zhu, L.; Han, G. W.; Moss, S. M.; Paoletta, S.; Kiselev, E.; Lu, W.; Fenalti, G.; Zhang, W.; Muller, C. E.; Yang, H.; Jiang, H.; Cherezov, V.; Katritch, V.; Jacobson, K. A.; Stevens, R. C.; Wu, B.; Zhao, Q. Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature 2014, 509, 115-118.

100. Wu, B.; Chien, E. Y.; Mol, C. D.; Fenalti, G.; Liu, W.; Katritch, V.; Abagyan, R.; Brooun, A.; Wells, P.; Bi, F. C.; Hamel, D. J.; Kuhn, P.; Handel, T. M.; Cherezov, V.; Stevens, R. C. Structures of the CXCR4 chemokine GPCR with small-mol-ecule and cyclic peptide antagonists. Science 2010, 330, 1066-1071.

101. Miller-Gallacher, J. L.; Nehme, R.; Warne, T.; Edwards, P. C.; Schertler, G. F.; Leslie, A. G.; Tate, C. G. The 2.1 A Resolution Structure of Cyanopindolol-Bound beta1-Adrenoceptor Identifies an Intramembrane Na+ Ion that Stabilises the Ligand-Free Receptor. PloS one 2014, 9, e92727.

102. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal struc-ture of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318, 1258-1265.

103. Ring, A. M.; Manglik, A.; Kruse, A. C.; Enos, M. D.; Weis, W. I.; Garcia, K. C.; Kobilka, B. K. Adrenaline-activated structure of beta-adre-noceptor stabilized by an engineered nano-body. Nature 2013.

104. Rasmussen, S. G.; DeVree, B. T.; Zou, Y.; Kruse, A. C.; Chung, K. Y.; Kobilka, T. S.; Thian, F. S.; Chae, P. S.; Pardon, E.; Calinski, D.; Mathiesen, J. M.; Shah, S. T.; Lyons, J. A.; Caffrey, M.; Gell-man, S. H.; Steyaert, J.; Skiniotis, G.; Weis, W. I.; Sunahara, R. K.; Kobilka, B. K. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 2011, 477, 549-555.

105. Warne, T.; Edwards, P. C.; Leslie, A. G.; Tate, C. G. Crystal structures of a stabilized beta1-ad-renoceptor bound to the biased agonists bu-cindolol and carvedilol. Structure 2012, 20, 841-849.

106. Weierstall, U.; James, D.; Wang, C.; White, T. A.; Wang, D.; Liu, W.; Spence, J. C.; Bruce Doak, R.; Nelson, G.; Fromme, P.; Fromme, R.; Grot-johann, I.; Kupitz, C.; Zatsepin, N. A.; Liu, H.; Basu, S.; Wacker, D.; Han, G. W.; Katritch, V.; Boutet, S.; Messerschmidt, M.; Williams, G. J.; Koglin, J. E.; Marvin Seibert, M.; Klinker, M.; Gati, C.; Shoeman, R. L.; Barty, A.; Chapman, H. N.; Kirian, R. A.; Beyerlein, K. R.; Stevens, R. C.; Li, D.; Shah, S. T.; Howe, N.; Caffrey, M.; Cherezov, V. Lipidic cubic phase injector facil-itates membrane protein serial femtosecond crystallography. Nat Commun 2014, 5, 3309.

107. Wu, H.; Wang, C.; Gregory, K. J.; Han, G. W.; Cho, H. P.; Xia, Y.; Niswender, C. M.; Katritch, V.; Meiler, J.; Cherezov, V.; Conn, P. J.; Stevens, R. C. Structure of a class C GPCR metabo-tropic glutamate receptor 1 bound to an al-losteric modulator. Science 2014, 344, 58-64.

182

References

R R

108. Dore, A. S.; Okrasa, K.; Patel, J. C.; Serrano-Ve-ga, M.; Bennett, K.; Cooke, R. M.; Errey, J. C.; Jazayeri, A.; Khan, S.; Tehan, B.; Weir, M.; Wig-gin, G. R.; Marshall, F. H. Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature 2014, advance online publication.

109. Liu, W.; Chun, E.; Thompson, A. A.; Chubukov, P.; Xu, F.; Katritch, V.; Han, G. W.; Roth, C. B.; Heitman, L. H.; AP, I. J.; Cherezov, V.; Stevens, R. C. Structural basis for allosteric regulation of GPCRs by sodium ions. Science 2012, 337, 232-236.

110. Fenalti, G.; Giguere, P. M.; Katritch, V.; Huang, X. P.; Thompson, A. A.; Cherezov, V.; Roth, B. L.; Stevens, R. C. Molecular control of del-ta-opioid receptor signalling. Nature 2014, 506, 191-196.

111. Zhang, C.; Srinivasan, Y.; Arlow, D. H.; Fung, J. J.; Palmer, D.; Zheng, Y.; Green, H. F.; Pandey, A.; Dror, R. O.; Shaw, D. E.; Weis, W. I.; Cough-lin, S. R.; Kobilka, B. K. High-resolution crystal structure of human protease-activated recep-tor 1. Nature 2012, 492, 387-392.

112. Gutierrez-de-Teran, H.; Massink, A.; Rodriguez, D.; Liu, W.; Han, G. W.; Joseph, J. S.; Katritch, I.; Heitman, L. H.; Xia, L.; Ijzerman, A. P.; Cherezov, V.; Katritch, V.; Stevens, R. C. The role of a so-dium ion binding site in the allosteric modula-tion of the A(2A) adenosine G protein-coupled receptor. Structure 2013, 21, 2175-2185.

113. Katritch, V.; Fenalti, G.; Abola, E. E.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Allosteric sodium in class A GPCR signaling. Trends Biochem Sci 2014, 39, 233-244.

114. Congreve, M.; Langmead, C. J.; Mason, J. S.; Marshall, F. H. Progress in structure based drug design for g protein-coupled receptors. J Med Chem 2011, 54, 4283-4311.

115. de Graaf, C.; Rognan, D. Customizing G Pro-tein-coupled receptor models for struc-ture-based virtual screening. Curr Pharm Des 2009, 15, 4026-4048.

116. Salon, J. A.; Lodowski, D. T.; Palczewski, K. The significance of g protein-coupled receptor crystallography for drug discovery. Pharmacol Rev 2011, 63, 901-937.

117. Granier, S.; Kobilka, B. A new era of GPCR structural and chemical biology. Nat Chem Biol 2012, 8, 670-673.

118. Katritch, V.; Cherezov, V.; Stevens, R. C. Diver-

sity and modularity of G protein-coupled re-ceptor structures. Trends Pharmacol Sci 2012, 33, 17-27.

119. Rodriguez, D.; Gutierrez-de-Teran, H. Compu-tational Approaches for Ligand Discovery and Design in Class-A G Protein-Coupled Recep-tors. Curr Pharm Des 2012.

120. Miller, L. J.; Chen, Q.; Lam, P. C.; Pinon, D. I.; Sexton, P. M.; Abagyan, R.; Dong, M. Refine-ment of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling. J Biol Chem 2011, 286, 15895-15907.

121. Vohra, S.; Taddese, B.; Conner, A. C.; Poyner, D. R.; Hay, D. L.; Barwell, J.; Reeves, P. J.; Upton, G. J.; Reynolds, C. A. Similarity between class A and class B G-protein-coupled receptors exemplified through calcitonin gene-related peptide receptor modelling and mutagenesis studies. J R Soc Interface 2013, 10, 20120846.

122. de Graaf, C.; Rein, C.; Piwnica, D.; Giordanet-to, F.; Rognan, D. Structure-based discovery of allosteric modulators of two related class B G-protein-coupled receptors. ChemMedChem 2011, 6, 2159-2169.

123. Petrel, C.; Kessler, A.; Dauban, P.; Dodd, R. H.; Rognan, D.; Ruat, M. Positive and nega-tive allosteric modulators of the Ca2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J Biol Chem 2004, 279, 18990-18997.

124. Malherbe, P.; Kratochwil, N.; Muhlemann, A.; Zenner, M. T.; Fischer, C.; Stahl, M.; Gerber, P. R.; Jaeschke, G.; Porter, R. H. Comparison of the binding pockets of two chemically un-related allosteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP. J Neurochem 2006, 98, 601-615.

125. Gloriam, D. E.; Wellendorph, P.; Johansen, L. D.; Thomsen, A. R.; Phonekeo, K.; Pedersen, D. S.; Brauner-Osborne, H. Chemogenomic discovery of allosteric antagonists at the GPR-C6A receptor. Chem Biol 2011, 18, 1489-1498.

126. Roumen, L.; Sanders, M. P.; Vroling, B.; de Esch, I. J.; de Vlieg, J.; Leurs, R.; Klomp, J. P.; Nabuurs, S. B.; de Graaf, C. In Silico Veritas: The Pitfalls and Challenges of Predicting GP-CR-Ligand Interactions. Pharmaceuticals 2011, 4, 1196-1215.

127. Katritch, V.; Rueda, M.; Lam, P. C.; Yeager, M.;

183

References

R R

Abagyan, R. GPCR 3D homology models for ligand screening: lessons learned from blind predictions of adenosine A2a receptor com-plex. Proteins 2010, 78, 197-211.

128. Michino, M.; Abola, E.; participants, G. D.; Brooks, C. L., 3rd; Dixon, J. S.; Moult, J.; Ste-vens, R. C. Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008. Nat Rev Drug Discov 2009, 8, 455-463.

129. Kufareva, I.; Rueda, M.; Katritch, V.; Stevens, R. C.; Abagyan, R.; participants, G. D. Status of GPCR Modeling and Docking as Reflected by Community-wide GPCR Dock 2010 Assess-ment. Structure 2011, 19, 1108-1126.

130. Kufareva, I.; Katritch, V.; Participants of, G. D.; Stevens, R. C.; Abagyan, R. Advances in GPCR Modeling Evaluated by the GPCR Dock 2013 Assessment: Meeting New Challenges. Struc-ture 2014, 22, 1120-1139.

131. Cavasotto, C. N. Homology models in docking and high-throughput docking. Curr Top Med Chem 2011, 11, 1528-1534.

132. Kooistra, A. J.; Roumen, L.; Leurs, R.; de Esch, I. J. P.; de Graaf, C. From Heptahelical Bundle to Hits from the Haystack: Structure-Based Virtual Screening for GPCR Ligands. G Protein Coupled Receptors Modeling, Activation, Interac-tions and Virtual Screening 2013, 522, 279-336.

133. Jaakola, V. P.; Griffith, M. T.; Hanson, M. A.; Cherezov, V.; Chien, E. Y.; Lane, J. R.; Ijzerman, A. P.; Stevens, R. C. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008, 322, 1211-1217.

134. Chien, E. Y.; Liu, W.; Zhao, Q.; Katritch, V.; Han, G. W.; Hanson, M. A.; Shi, L.; Newman, A. H.; Javitch, J. A.; Cherezov, V.; Stevens, R. C. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 2010, 330, 1091-1095.

135. Cherezov, V.; Abola, E.; Stevens, R. C. Recent progress in the structure determination of GP-CRs, a membrane protein family with high po-tential as pharmaceutical targets. Methods Mol Biol 2010, 654, 141-168.

136. Lagerstrom, M. C.; Schioth, H. B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discovery 2008, 7, 339-357.

137. Moura Barbosa, A. J.; Del Rio, A. Freely acces-

sible databases of commercial compounds for high- throughput virtual screenings. Curr Top Med Chem 2012, 12, 866-877.

138. Baell, J. B.; Holloway, G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 2010, 53, 2719-2740.

139. Muegge, I. Selection criteria for drug-like com-pounds. Med Res Rev 2003, 23, 302-321.

140. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and perme-ability in drug discovery and development set-tings. Adv Drug Deliv Rev 2001, 46, 3-26.

141. Varady, J.; Wu, X.; Fang, X.; Min, J.; Hu, Z.; Le-vant, B.; Wang, S. Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmaco-phore- and structure-based database searching approach. J Med Chem 2003, 46, 4377-4392.

142. Evers, A.; Klabunde, T. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. J Med Chem 2005, 48, 1088-1097.

143. Evers, A.; Klebe, G. Successful virtual screening for a submicromolar antagonist of the neuro-kinin-1 receptor based on a ligand-supported homology model. J Med Chem 2004, 47, 5381-5392.

144. Kellenberger, E.; Springael, J. Y.; Parmentier, M.; Hachet-Haas, M.; Galzi, J. L.; Rognan, D. Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. J Med Chem 2007, 50, 1294-1303.

145. Cavasotto, C. N.; Orry, A. J.; Murgolo, N. J.; Czarniecki, M. F.; Kocsi, S. A.; Hawes, B. E.; O'Neill, K. A.; Hine, H.; Burton, M. S.; Voigt, J. H.; Abagyan, R. A.; Bayne, M. L.; Monsma, F. J., Jr. Discovery of novel chemotypes to a G-pro-tein-coupled receptor through ligand-steered homology modeling and structure-based virtu-al screening. J Med Chem 2008, 51, 581-588.

146. Tikhonova, I. G.; Sum, C. S.; Neumann, S.; En-gel, S.; Raaka, B. M.; Costanzi, S.; Gershengorn, M. C. Discovery of novel agonists and antago-nists of the free fatty acid receptor 1 (FFAR1) using virtual screening. J Med Chem 2008, 51, 625-633.

184

References

R R

147. Evers, A.; Hessler, G.; Matter, H.; Klabunde, T. Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtu-al screening protocols. J Med Chem 2005, 48, 5448-5465.

148. Olah, H.; Rad, R.; Ostopovici, L.; Bora, A.; Ha-daruga, N.; Hadaruga, D.; Moldovan, R.; Fulias, A.; Mracec, M.; Oprea, T. I. WOMBAT and WOMBAT-PK: Bioactivity Databases for Lead and Drug Discovery. . In Chemical Biology: From Small Molecules to Systems Biology and Drug Design, 2005/08/25 ed.; SL Schreiber, T. K., G. Wess (Eds.), Ed. Wiley-VCH: New York, 2007; pp pp. 760-786.

149. Moitessier, N.; Englebienne, P.; Lee, D.; Lawa-ndi, J.; Corbeil, C. R. Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go. Br J Phar-macol 2008, 153 Suppl 1, S7-26.

150. Sirci, F.; Istyastono, E. P.; Vischer, H. F.; Koo-istra, A. J.; Nijmeijer, S.; Kuijer, M.; Wijtmans, M.; Mannhold, R.; Leurs, R.; de Esch, I. J.; de Graaf, C. Virtual fragment screening: discov-ery of histamine h(3) receptor ligands using ligand-based and protein-based molecular fingerprints. J Chem Inf Model 2012, 52, 3308-3324.

151. Klabunde, T.; Giegerich, C.; Evers, A. Se-quence-derived three-dimensional pharmaco-phore models for G-protein-coupled receptors and their application in virtual screening. J Med Chem 2009, 52, 2923-2932.

152. Salo, O. M.; Raitio, K. H.; Savinainen, J. R.; Ne-valainen, T.; Lahtela-Kakkonen, M.; Laitinen, J. T.; Jarvinen, T.; Poso, A. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. J Med Chem 2005, 48, 7166-7171.

153. Edwards, B. S.; Bologa, C.; Young, S. M.; Bal-akin, K. V.; Prossnitz, E. R.; Savchuck, N. P.; Sklar, L. A.; Oprea, T. I. Integration of virtual screening with high-throughput flow cytom-etry to identify novel small molecule formyl-peptide receptor antagonists. Mol Pharmacol 2005, 68, 1301-1310.

154. Bissantz, C.; Bernard, P.; Hibert, M.; Rognan, D. Protein-based virtual screening of chemical databases. II. Are homology models of G-Pro-tein Coupled Receptors suitable targets? Pro-teins 2003, 50, 5-25.

155. Chen, J. Z.; Wang, J.; Xie, X. Q. GPCR struc-ture-based virtual screening approach for CB2 antagonist search. J Chem Inf Model 2007, 47, 1626-1637.

156. Kiss, R.; Kiss, B.; Konczol, A.; Szalai, F.; Jelinek, I.; Laszlo, V.; Noszal, B.; Falus, A.; Keseru, G. M. Discovery of novel human histamine H4 re-ceptor ligands by large-scale structure-based virtual screening. J Med Chem 2008, 51, 3145-3153.

157. Carlsson, J.; Coleman, R. G.; Setola, V.; Irwin, J. J.; Fan, H.; Schlessinger, A.; Sali, A.; Roth, B. L.; Shoichet, B. K. Ligand discovery from a dopa-mine D3 receptor homology model and crystal structure. Nat Chem Biol 2011, 7, 769-778.

158. Carlsson, J.; Yoo, L.; Gao, Z. G.; Irwin, J. J.; Shoichet, B. K.; Jacobson, K. A. Structure-based discovery of A2A adenosine receptor ligands. J Med Chem 2010, 53, 3748-3755.

159. Langmead, C. J.; Andrews, S. P.; Congreve, M.; Errey, J. C.; Hurrell, E.; Marshall, F. H.; Mason, J. S.; Richardson, C. M.; Robertson, N.; Zhukov, A.; Weir, M. Identification of Novel Adenosine A2A Receptor Antagonists by Virtual Screen-ing. J Med Chem 2012, 55, 1904-1909.

160. de Graaf, C.; Foata, N.; Engkvist, O.; Rognan, D. Molecular modeling of the second extra-cellular loop of G-protein coupled receptors and its implication on structure-based virtual screening. Proteins 2008, 71, 599-620.

161. de Graaf, C.; Kooistra, A. J.; Vischer, H. F.; Ka-tritch, V.; Kuijer, M.; Shiroishi, M.; Iwata, S.; Shi-mamura, T.; Stevens, R. C.; de Esch, I. J.; Leurs, R. Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. J Med Chem 2011, 54, 8195-8206.

162. de Graaf, C.; Rognan, D. Selective struc-ture-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. J Med Chem 2008, 51, 4978-4985.

163. Katritch, V.; Jaakola, V. P.; Lane, J. R.; Lin, J.; Ijzerman, A. P.; Yeager, M.; Kufareva, I.; Ste-vens, R. C.; Abagyan, R. Structure-based dis-covery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem 2010, 53, 1799-1809.

164. Kolb, P.; Rosenbaum, D. M.; Irwin, J. J.; Fung, J. J.; Kobilka, B. K.; Shoichet, B. K. Struc-ture-based discovery of beta2-adrenergic re-ceptor ligands. Proc Natl Acad Sci U S A 2009,

185

References

R R

106, 6843-6848.165. Barillari, C.; Marcou, G.; Rognan, D. Hot-spots-

guided receptor-based pharmacophores (HS-Pharm): a knowledge-based approach to iden-tify ligand-anchoring atoms in protein cavities and prioritize structure-based pharmacoph-ores. J Chem Inf Model 2008, 48, 1396-1410.

166. Kolb, P.; Phan, K.; Gao, Z. G.; Marko, A. C.; Sali, A.; Jacobson, K. A. Limits of ligand selectivity from docking to models: in silico screening for A(1) adenosine receptor antagonists. PloS one 2012, 7, e49910.

167. Congreve, M.; Andrews, S. P.; Dore, A. S.; Hol-lenstein, K.; Hurrell, E.; Langmead, C. J.; Ma-son, J. S.; Ng, I. W.; Tehan, B.; Zhukov, A.; Weir, M.; Marshall, F. H. Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists us-ing structure based drug design. J Med Chem 2012, 55, 1898-1903.

168. Andrews, S. P. T., B. Stabilised G Protein-Cou-pled Receptors in Structure-Based Drug De-sign: A Case Study with Adenosine A2A Recep-tor. Med Chem Commun 2013, 4, 52-67.

169. Lin, X.; Huang, X. P.; Chen, G.; Whaley, R.; Peng, S.; Wang, Y.; Zhang, G.; Wang, S. X.; Wang, S.; Roth, B. L.; Huang, N. Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors. J Med Chem 2012, 55, 5749-5759.

170. Istyastono, E. P. Computational Studies of His-tamine H4 Receptor-Ligand Interactions. VU University Amsterdam, Amsterdam, 2012.

171. Blättermann, S.; Peters, L.; Ottersbach, P. A.; Bock, A.; Konya, V.; Weaver, C. D.; Gonzalez, A.; Schroder, R.; Tyagi, R.; Luschnig, P.; Gab, J.; Hennen, S.; Ulven, T.; Pardo, L.; Mohr, K.; Gutschow, M.; Heinemann, A.; Kostenis, E. A biased ligand for OXE-R uncouples Galpha and Gbetagamma signaling within a heterotrimer. Nat Chem Biol 2012, 8, 631-638.

172. Kim, J.; Yip, M. L.; Shen, X.; Li, H.; Hsin, L. Y.; La-barge, S.; Heinrich, E. L.; Lee, W.; Lu, J.; Vaide-hi, N. Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells. PloS one 2012, 7, e31004.

173. Mysinger, M. M.; Weiss, D. R.; Ziarek, J. J.; Gravel, S.; Doak, A. K.; Karpiak, J.; Heveker, N.; Shoichet, B. K.; Volkman, B. F. Structure-based ligand discovery for the protein-protein inter-face of chemokine receptor CXCR4. Proc Natl

Acad Sci U S A 2012, 109, 5517-5522.174. Renault, N.; Laurent, X.; Farce, A.; El Bakali,

J.; Mansouri, R.; Gervois, P.; Millet, R.; Des-reumaux, P.; Furman, C.; Chavatte, P. Virtual screening of CB(2) receptor agonists from bayesian network and high-throughput dock-ing: structural insights into agonist-modulated GPCR features. Chem Biol Drug Des 2013, 81, 442-454.

175. Costanzi, S.; Santhosh Kumar, T.; Balasubrama-nian, R.; Kendall Harden, T.; Jacobson, K. A. Vir-tual screening leads to the discovery of novel non-nucleotide P2Y(1) receptor antagonists. Bioorg Med Chem 2012, 20, 5254-5261.

176. Katritch, V.; Cherezov, V.; Stevens, R. C. Struc-ture-function of the G protein-coupled recep-tor superfamily. Annu Rev Pharmacol Toxicol 2013, 53, 531-556.

177. Topiol, S.; Sabio, M. Use of the X-ray structure of the Beta2-adrenergic receptor for drug dis-covery. Bioorg Med Chem Lett 2008, 18, 1598-1602.

178. Sabio, M.; Jones, K.; Topiol, S. Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. Bioorg Med Chem Lett 2008, 18, 5391-5395.

179. Becker, O. M.; Marantz, Y.; Shacham, S.; Inbal, B.; Heifetz, A.; Kalid, O.; Bar-Haim, S.; War-shaviak, D.; Fichman, M.; Noiman, S. G pro-tein-coupled receptors: in silico drug discov-ery in 3D. Proc Natl Acad Sci U S A 2004, 101, 11304-11309.

180. Engel, S.; Skoumbourdis, A. P.; Childress, J.; Neumann, S.; Deschamps, J. R.; Thomas, C. J.; Colson, A. O.; Costanzi, S.; Gershengorn, M. C. A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antag-onists. J Am Chem Soc 2008, 130, 5115-5123.

181. Liu, Y.; Zhou, E.; Yu, K.; Zhu, J.; Zhang, Y.; Xie, X.; Li, J.; Jiang, H. Discovery of a novel CCR5 antagonist lead compound through fragment assembly. Molecules 2008, 13, 2426-2441.

182. Triballeau, N.; Van Name, E.; Laslier, G.; Cai, D.; Paillard, G.; Sorensen, P. W.; Hoffmann, R.; Bertrand, H. O.; Ngai, J.; Acher, F. C. High-po-tency olfactory receptor agonists discovered by virtual high-throughput screening: molecu-lar probes for receptor structure and olfactory function. Neuron 2008, 60, 767-774.

183. van der Horst, E.; Okuno, Y.; Bender, A.; AP, I.

186

References

R R

J. Substructure mining of GPCR ligands reveals activity-class specific functional groups in an unbiased manner. J Chem Inf Model 2009, 49, 348-360.

184. Kim, J.; Wess, J.; van Rhee, A. M.; Schoneberg, T.; Jacobson, K. A. Site-directed mutagenesis identifies residues involved in ligand recogni-tion in the human A2a adenosine receptor. J Biol Chem 1995, 270, 13987-13997.

185. Jaakola, V. P.; Lane, J. R.; Lin, J. Y.; Katritch, V.; Ijzerman, A. P.; Stevens, R. C. Ligand binding and subtype selectivity of the human A(2A) ad-enosine receptor: identification and character-ization of essential amino acid residues. J Biol Chem 2010, 285, 13032-13044.

186. Zhukov, A.; Andrews, S. P.; Errey, J. C.; Robert-son, N.; Tehan, B.; Mason, J. S.; Marshall, F. H.; Weir, M.; Congreve, M. Biophysical mapping of the adenosine A2A receptor. J Med Chem 2011, 54, 4312-4323.

187. Hanson, M. A.; Cherezov, V.; Griffith, M. T.; Roth, C. B.; Jaakola, V. P.; Chien, E. Y.; Velas-quez, J.; Kuhn, P.; Stevens, R. C. A specific cho-lesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic re-ceptor. Structure 2008, 16, 897-905.

188. Keiser, M. J.; Roth, B. L.; Armbruster, B. N.; Ernsberger, P.; Irwin, J. J.; Shoichet, B. K. Relat-ing protein pharmacology by ligand chemistry. Nat Biotechnol 2007, 25, 197-206.

189. Yrjola, S.; Kalliokoski, T.; Laitinen, T.; Poso, A.; Parkkari, T.; Nevalainen, T. Discovery of nov-el cannabinoid receptor ligands by a virtual screening approach: Further development of 2,4,6-trisubstituted 1,3,5-triazines as CB2 ago-nists. Eur J Pharm Sci 2013, 48, 9-20.

190. Congreve, M.; Rich, R. L.; Myszka, D. G.; Figa-roa, F.; Siegal, G.; Marshall, F. H. Fragment screening of stabilized G-protein-coupled re-ceptors using biophysical methods. Methods Enzymol 2011, 493, 115-136.

191. Tautermann, C. S. The use of G-protein cou-pled receptor models in lead optimization. Fu-ture Med Chem 2011, 3, 709-721.

192. Becker, O. M.; Dhanoa, D. S.; Marantz, Y.; Chen, D.; Shacham, S.; Cheruku, S.; Heifetz, A.; Mohanty, P.; Fichman, M.; Sharadendu, A.; Nudelman, R.; Kauffman, M.; Noiman, S. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfon-amide 5-HT1A agonist (PRX-00023) for the

treatment of anxiety and depression. J Med Chem 2006, 49, 3116-3135.

193. Wacker, D.; Fenalti, G.; Brown, M. A.; Katritch, V.; Abagyan, R.; Cherezov, V.; Stevens, R. C. Conserved binding mode of human beta2 ad-renergic receptor inverse agonists and antag-onist revealed by X-ray crystallography. J Am Chem Soc 2010, 132, 11443-11445.

194. Kiss, G. N.; Fells, J. I.; Gupte, R.; Lee, S. C.; Liu, J.; Nusser, N.; Lim, K. G.; Ray, R. M.; Lin, F. T.; Parrill, A. L.; Sumegi, B.; Miller, D. D.; Tigyi, G. Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapop-totic actions. Mol Pharmacol 2012, 82, 1162-1173.

195. Tosh, D. K.; Phan, K.; Gao, Z. G.; Gakh, A. A.; Xu, F.; Deflorian, F.; Abagyan, R.; Stevens, R. C.; Jacobson, K. A.; Katritch, V. Optimization of adenosine 5'-carboxamide derivatives as ade-nosine receptor agonists using structure-based ligand design and fragment screening. J Med Chem 2012, 55, 4297-4308.

196. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discov Today 2004, 9, 430-431.

197. Leach, A. R.; Hann, M. M. Molecular complexity and fragment-based drug discovery: ten years on. Curr Opin Chem Biol 2011, 15, 489-496.

198. Loving, K.; Alberts, I.; Sherman, W. Computa-tional approaches for fragment-based and de novo design. Curr Top Med Chem 2010, 10, 14-32.

199. Kruse, A. C.; Hu, J.; Pan, A. C.; Arlow, D. H.; Rosenbaum, D. M.; Rosemond, E.; Green, H. F.; Liu, T.; Chae, P. S.; Dror, R. O.; Shaw, D. E.; Weis, W. I.; Wess, J.; Kobilka, B. K. Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 2012, 482, 552-556.

200. Dror, R. O.; Pan, A. C.; Arlow, D. H.; Borhani, D. W.; Maragakis, P.; Shan, Y.; Xu, H.; Shaw, D. E. Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc Natl Acad Sci U S A 2011, 108, 13118-13123.

201. Tresadern, G.; Bartolome, J. M.; Macdonald, G. J.; Langlois, X. Molecular properties affecting fast dissociation from the D2 receptor. Bioorg Med Chem 2011, 19, 2231-2241.

202. Miller, D. C.; Lunn , G.; Jones , P.; Sabnis , Y.; Davies, N. L.; Driscoll, P. Investigation of the effect of molecular properties on the binding kinetics of a ligand to its biological target. Med.

187

References

R R

Chem. Comm. 2012, 3, 449-452.203. Katritch, V.; Abagyan, R. GPCR agonist bind-

ing revealed by modeling and crystallography. Trends Pharmacol Sci 2011, 32, 637-643.

204. Rosenkilde, M. M.; Benned-Jensen, T.; Frim-urer, T. M.; Schwartz, T. W. The minor binding pocket: a major player in 7TM receptor activa-tion. Trends Pharmacol Sci 2010, 31, 567-574.

205. Liu, J. J.; Horst, R.; Katritch, V.; Stevens, R. C.; Wuthrich, K. Biased signaling pathways in beta2-adrenergic receptor characterized by 19F-NMR. Science 2012, 335, 1106-1110.

206. Bokoch, M. P.; Zou, Y.; Rasmussen, S. G.; Liu, C. W.; Nygaard, R.; Rosenbaum, D. M.; Fung, J. J.; Choi, H. J.; Thian, F. S.; Kobilka, T. S.; Puglisi, J. D.; Weis, W. I.; Pardo, L.; Prosser, R. S.; Mueller, L.; Kobilka, B. K. Ligand-specific regulation of the extracellular surface of a G-protein-cou-pled receptor. Nature 2010, 463, 108-112.

207. Klabunde, T. Chemogenomic approaches to drug discovery: similar receptors bind similar ligands. Br J Pharmacol 2007, 152, 5-7.

208. Rognan, D. Chemogenomic approaches to ra-tional drug design. Br J Pharmacol 2007, 152, 38-52.

209. Garland, S. L.; Gloriam, D. E. Methods for the successful application of chemogenomics to GPCR drug design. Curr Top Med Chem 2011, 11, 1870-1871.

210. Overington, J. P.; Al-Lazikani, B.; Hopkins, A. L. How many drug targets are there? Nat Rev Drug Discov 2006, 5, 993-996.

211. Jacoby, E.; Bouhelal, R.; Gerspacher, M.; Seu-wen, K. The 7 TM G-protein-coupled receptor target family. ChemMedChem 2006, 1, 761-782.

212. Brianso, F.; Carrascosa, M. C.; Oprea, T. I.; Mestres, J. Cross-pharmacology analysis of G protein-coupled receptors. Curr Top Med Chem 2011, 11, 1956-1963.

213. Sanders, M. P.; Roumen, L.; van der Horst, E.; Lane, J. R.; Vischer, H. F.; van Offenbeek, J.; de Vries, H.; Verhoeven, S.; Chow, K. Y.; Verkaar, F.; Beukers, M. W.; McGuire, R.; Leurs, R.; Ijzer-man, A. P.; de Vlieg, J.; de Esch, I. J.; Zaman, G. J.; Klomp, J. P.; Bender, A.; de Graaf, C. A prospective cross-screening study on G-pro-tein-coupled receptors: lessons learned in virtual compound library design. J Med Chem 2012, 55, 5311-5325.

214. Besnard, J.; Ruda, G. F.; Setola, V.; Abecassis, K.; Rodriguiz, R. M.; Huang, X. P.; Norval, S.;

Sassano, M. F.; Shin, A. I.; Webster, L. A.; Sim-eons, F. R.; Stojanovski, L.; Prat, A.; Seidah, N. G.; Constam, D. B.; Bickerton, G. R.; Read, K. D.; Wetsel, W. C.; Gilbert, I. H.; Roth, B. L.; Hopkins, A. L. Automated design of ligands to polypharmacological profiles. Nature 2012, 492, 215-220.

215. Morphy, R.; Rankovic, Z. Designed multiple li-gands. An emerging drug discovery paradigm. J Med Chem 2005, 48, 6523-6543.

216. Keiser, M. J.; Setola, V.; Irwin, J. J.; Laggner, C.; Abbas, A. I.; Hufeisen, S. J.; Jensen, N. H.; Kui-jer, M. B.; Matos, R. C.; Tran, T. B.; Whaley, R.; Glennon, R. A.; Hert, J.; Thomas, K. L.; Edwards, D. D.; Shoichet, B. K.; Roth, B. L. Predicting new molecular targets for known drugs. Nature 2009, 462, 175-181.

217. Gloriam, D. E.; Foord, S. M.; Blaney, F. E.; Gar-land, S. L. Definition of the G protein-cou-pled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design. J Med Chem 2009, 52, 4429-4442.

218. Attwood, T. K.; Findlay, J. B. Fingerprinting G-protein-coupled receptors. Protein Eng 1994, 7, 195-203.

219. Johansson, H.; Jørgensen, T. B.; Gloriam, D. E.; Bräuner-Osborne, H.; Pedersen, D. S. 3-Substi-tuted 2-phenyl-indoles: privileged structures for medicinal chemistry. RSC Adv 2013, 3, 945-960.

220. Bondensgaard, K.; Ankersen, M.; Thogersen, H.; Hansen, B. S.; Wulff, B. S.; Bywater, R. P. Recognition of privileged structures by G-pro-tein coupled receptors. J Med Chem 2004, 47, 888-899.

221. Garland, S. L.; Gloriam, D. E. A ligand's view of target similarity: chemogenomic binding site-directed techniques for drug discovery. Curr Top Med Chem 2011, 11, 1872-1881.

222. Weill, N.; Rognan, D. Development and vali-dation of a novel protein-ligand fingerprint to mine chemogenomic space: application to G protein-coupled receptors and their ligands. J Chem Inf Model 2009, 49, 1049-1062.

223. Weill, N. Chemogenomic approaches for the exploration of GPCR space. Curr Top Med Chem 2011, 11, 1944-1955.

224. Chen, X.; Lin, Y.; Gilson, M. K. The binding da-tabase: overview and user's guide. Biopolymers 2001, 61, 127-141.

188

References

R R

225. Shi, L.; Javitch, J. A. The binding site of amin-ergic G protein-coupled receptors: the trans-membrane segments and second extracellular loop. Annu Rev Pharmacol Toxicol 2002, 42, 437-467.

226. Paolini, G. V.; Shapland, R. H.; van Hoorn, W. P.; Mason, J. S.; Hopkins, A. L. Global mapping of pharmacological space. Nat Biotechnol 2006, 24, 805-815.

227. Simons, F. E.; Simons, K. J. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011, 128, 1139-1150 e1134.

228. Kuhne, S.; Wijtmans, M.; Lim, H. D.; Leurs, R.; de Esch, I. J. Several down, a few to go: hista-mine H3 receptor ligands making the final push towards the market? Expert Opin Investig Drugs 2011, 20, 1629-1648.

229. Engelhardt, H.; Smits, R. A.; Leurs, R.; Haaks-ma, E.; de Esch, I. J. A new generation of an-ti-histamines: Histamine H4 receptor antago-nists on their way to the clinic. Curr Opin Drug Discov Devel 2009, 12, 628-643.

230. Parsons, M. E.; Ganellin, C. R. Histamine and its receptors. Br J Pharmacol 2006, 147 Suppl 1, S127-135.

231. Kiss, R.; Keseru, G. M. Histamine H4 receptor ligands and their potential therapeutic applica-tions: an update. Expert Opin Ther Pat 2012, 22, 205-221.

232. Vroling, B.; Sanders, M.; Baakman, C.; Borr-mann, A.; Verhoeven, S.; Klomp, J.; Oliveira, L.; de Vlieg, J.; Vriend, G. GPCRDB: information system for G protein-coupled receptors. Nu-cleic Acids Res 2011, 39, D309-319.

233. Haga, K.; Kruse, A. C.; Asada, H.; Yurugi-Ko-bayashi, T.; Shiroishi, M.; Zhang, C.; Weis, W. I.; Okada, T.; Kobilka, B. K.; Haga, T.; Kobayashi, T. Structure of the human M2 muscarinic acetyl-choline receptor bound to an antagonist. Na-ture 2012, 482, 547-551.

234. Alexander, S. P.; Mathie, A.; Peters, J. A. Guide to Receptors and Channels (GRAC), 5th edi-tion. Br J Pharmacol 2011, 164 Suppl 1, S1-324.

235. Jongejan, A.; Bruysters, M.; Ballesteros, J. A.; Haaksma, E.; Bakker, R. A.; Pardo, L.; Leurs, R. Linking agonist binding to histamine H1 recep-tor activation. Nat Chem Biol 2005, 1, 98-103.

236. Strasser, A.; Wittmann, H. J.; Kunze, M.; Elz, S.; Seifert, R. Molecular basis for the selective interaction of synthetic agonists with the hu-

man histamine H1-receptor compared with the guinea pig H1-receptor. Mol Pharmacol 2009, 75, 454-465.

237. Schlegel, B.; Laggner, C.; Meier, R.; Langer, T.; Schnell, D.; Seifert, R.; Stark, H.; Holtje, H. D.; Sippl, W. Generation of a homology model of the human histamine H(3) receptor for ligand docking and pharmacophore-based screening. J Comput Aided Mol Des 2007, 21, 437-453.

238. Jongejan, A.; Lim, H. D.; Smits, R. A.; de Esch, I. J.; Haaksma, E.; Leurs, R. Delineation of agonist binding to the human histamine H4 receptor using mutational analysis, homology model-ing, and ab initio calculations. J Chem Inf Model 2008, 48, 1455-1463.

239. Lim, H. D.; de Graaf, C.; Jiang, W.; Sadek, P.; McGovern, P. M.; Istyastono, E. P.; Bakker, R. A.; de Esch, I. J.; Thurmond, R. L.; Leurs, R. Mo-lecular determinants of ligand binding to H4R species variants. Mol Pharmacol 2010, 77, 734-743.

240. Kiss, R.; Noszal, B.; Racz, A.; Falus, A.; Eros, D.; Keseru, G. M. Binding mode analysis and en-richment studies on homology models of the human histamine H4 receptor. Eur J Med Chem 2008, 43, 1059-1070.

241. Kelley, M. T.; Burckstummer, T.; Wenzel-Seifert, K.; Dove, S.; Buschauer, A.; Seifert, R. Distinct interaction of human and guinea pig histamine H2-receptor with guanidine-type agonists. Mol Pharmacol 2001, 60, 1210-1225.

242. Werner, T.; Sander, K.; Tanrikulu, Y.; Kottke, T.; Proschak, E.; Stark, H.; Schneider, G. In silico characterization of ligand binding modes in the human histamine H4 receptor and their impact on receptor activation. Chembiochem 2010, 11, 1850-1855.

243. Jojart, B.; Kiss, R.; Viskolcz, B.; Keseru, G. M. Activation mechanism of the human histamine H4 receptor--an explicit membrane molecular dynamics simulation study. J Chem Inf Model 2008, 48, 1199-1210.

244. Igel, P.; Geyer, R.; Strasser, A.; Dove, S.; Seifert, R.; Buschauer, A. Synthesis and structure-ac-tivity relationships of cyanoguanidine-type and structurally related histamine H4 receptor ag-onists. J Med Chem 2009, 52, 6297-6313.

245. Seifert, R.; Strasser, A.; Schneider, E. H.; Neu-mann, D.; Dove, S.; Buschauer, A. Molecular and cellular analysis of human histamine recep-tor subtypes. Trends Pharmacol Sci 2013, 34,

189

References

R R

33-58.246. Istyastono, E. P. Structure-based virtual

fragment screening for ligands of the G pro-tein-coupled histamine H4 receptor. PhD The-sis. Division of medicinal chemistry - VU Universi-ty Amsterdam 2012.

247. Alberts, G. L.; Pregenzer, J. F.; Im, W. B. Contri-butions of cysteine 114 of the human D3 dopa-mine receptor to ligand binding and sensitivity to external oxidizing agents. Br J Pharmacol 1998, 125, 705-710.

248. Ambrosio, C.; Molinari, P.; Cotecchia, S.; Costa, T. Catechol-binding serines of beta(2)-adren-ergic receptors control the equilibrium be-tween active and inactive receptor states. Mol Pharmacol 2000, 57, 198-210.

249. Bakker, R. A.; Weiner, D. M.; ter Laak, T.; Beum-ing, T.; Zuiderveld, O. P.; Edelbroek, M.; Hack-sell, U.; Timmerman, H.; Brann, M. R.; Leurs, R. 8R-lisuride is a potent stereospecific histamine H1-receptor partial agonist. Mol Pharmacol 2004, 65, 538-549.

250. Bluml, K.; Mutschler, E.; Wess, J. Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic ace-tylcholine receptors. J Biol Chem 1994, 269, 18870-18876.

251. Bruysters, M.; Pertz, H. H.; Teunissen, A.; Bak-ker, R. A.; Gillard, M.; Chatelain, P.; Schunack, W.; Timmerman, H.; Leurs, R. Mutational analy-sis of the histamine H1-receptor binding pock-et of histaprodifens. Eur J Pharmacol 2004, 487, 55-63.

252. Dohlman, H. G.; Caron, M. G.; DeBlasi, A.; Fri-elle, T.; Lefkowitz, R. J. Role of extracellular di-sulfide-bonded cysteines in the ligand binding function of the beta 2-adrenergic receptor. Biochemistry 1990, 29, 2335-2342.

253. Dorfler, M.; Tschammer, N.; Hamperl, K.; Hubner, H.; Gmeiner, P. Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem 2008, 51, 6829-6838.

254. Ehrlich, K.; Gotz, A.; Bollinger, S.; Tschammer, N.; Bettinetti, L.; Harterich, S.; Hubner, H.; Lanig, H.; Gmeiner, P. Dopamine D2, D3, and D4 selective phenylpiperazines as molecular probes to explore the origins of subtype spe-cific receptor binding. J Med Chem 2009, 52,

4923-4935.255. Fraser, C. M. Site-directed mutagenesis of be-

ta-adrenergic receptors. Identification of con-served cysteine residues that independently affect ligand binding and receptor activation. J Biol Chem 1989, 264, 9266-9270.

256. Gantz, I.; DelValle, J.; Wang, L. D.; Tashiro, T.; Munzert, G.; Guo, Y. J.; Konda, Y.; Yamada, T. Molecular basis for the interaction of histamine with the histamine H2 receptor. J Biol Chem 1992, 267, 20840-20843.

257. Gillard, M.; Van Der Perren, C.; Moguilevsky, N.; Massingham, R.; Chatelain, P. Binding char-acteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). Mol Pharmacol 2002, 61, 391-399.

258. Gregory, K. J.; Hall, N. E.; Tobin, A. B.; Sexton, P. M.; Christopoulos, A. Identification of ortho-steric and allosteric site mutations in M2 mus-carinic acetylcholine receptors that contribute to ligand-selective signaling bias. J Biol Chem 2010, 285, 7459-7474.

259. Heitz, F.; Holzwarth, J. A.; Gies, J. P.; Pruss, R. M.; Trumpp-Kallmeyer, S.; Hibert, M. F.; Guen-et, C. Site-directed mutagenesis of the puta-tive human muscarinic M2 receptor binding site. Eur J Pharmacol 1999, 380, 183-195.

260. Hulme, E. C.; Curtis, C. A.; Page, K. M.; Jones, P. G. The role of charge interactions in musca-rinic agonist binding, and receptor-response coupling. Life Sci 1995, 56, 891-898.

261. Leurs, R.; Smit, M. J.; Meeder, R.; Ter Laak, A. M.; Timmerman, H. Lysine200 located in the fifth transmembrane domain of the histamine H1 receptor interacts with histamine but not with all H1 agonists. Biochem Biophys Res Com-mun 1995, 214, 110-117.

262. Leurs, R.; Smit, M. J.; Tensen, C. P.; Ter Laak, A. M.; Timmerman, H. Site-directed muta-genesis of the histamine H1-receptor reveals a selective interaction of asparagine207 with subclasses of H1-receptor agonists. Biochem Biophys Res Commun 1994, 201, 295-301.

263. Liapakis, G.; Ballesteros, J. A.; Papachristou, S.; Chan, W. C.; Chen, X.; Javitch, J. A. The for-gotten serine. A critical role for Ser-2035.42 in ligand binding to and activation of the beta 2-adrenergic receptor. J Biol Chem 2000, 275, 37779-37788.

264. Moguilevsky, N.; Varsalona, F.; Guillaume, J. P.;

190

References

R R

Noyer, M.; Gillard, M.; Daliers, J.; Henichart, J. P.; Bollen, A. Pharmacological and functional characterisation of the wild-type and site-di-rected mutants of the human H1 histamine re-ceptor stably expressed in CHO cells. J Recept Signal Transduct Res 1995, 15, 91-102.

265. Nonaka, H.; Otaki, S.; Ohshima, E.; Kono, M.; Kase, H.; Ohta, K.; Fukui, H.; Ichimura, M. Unique binding pocket for KW-4679 in the his-tamine H1 receptor. Eur J Pharmacol 1998, 345, 111-117.

266. Ohta, K.; Hayashi, H.; Mizuguchi, H.; Kagami-yama, H.; Fujimoto, K.; Fukui, H. Site-directed mutagenesis of the histamine H1 receptor: roles of aspartic acid107, asparagine198 and threonine194. Biochem Biophys Res Commun 1994, 203, 1096-1101.

267. Sartania, N.; Strange, P. G. Role of conserved serine residues in the interaction of agonists with D3 dopamine receptors. J Neurochem 1999, 72, 2621-2624.

268. Schmidt, C.; Li, B.; Bloodworth, L.; Erlenbach, I.; Zeng, F. Y.; Wess, J. Random mutagenesis of the M3 muscarinic acetylcholine recep-tor expressed in yeast. Identification of point mutations that "silence" a constitutively active mutant M3 receptor and greatly impair recep-tor/G protein coupling. J Biol Chem 2003, 278, 30248-30260.

269. Shin, N.; Coates, E.; Murgolo, N. J.; Morse, K. L.; Bayne, M.; Strader, C. D.; Monsma, F. J., Jr. Molecular modeling and site-specific mu-tagenesis of the histamine-binding site of the histamine H4 receptor. Mol Pharmacol 2002, 62, 38-47.

270. Suryanarayana, S.; Kobilka, B. K. Amino acid substitutions at position 312 in the seventh hy-drophobic segment of the beta 2-adrenergic receptor modify ligand-binding specificity. Mol Pharmacol 1993, 44, 111-114.

271. Uveges, A. J.; Kowal, D.; Zhang, Y.; Spangler, T. B.; Dunlop, J.; Semus, S.; Jones, P. G. The role of transmembrane helix 5 in agonist binding to the human H3 receptor. J Pharmacol Exp Ther 2002, 301, 451-458.

272. Wess, J.; Gdula, D.; Brann, M. R. Site-directed mutagenesis of the m3 muscarinic receptor: identification of a series of threonine and ty-rosine residues involved in agonist but not an-tagonist binding. EMBO J 1991, 10, 3729-3734.

273. Wess, J.; Nanavati, S.; Vogel, Z.; Maggio, R.

Functional role of proline and tryptophan res-idues highly conserved among G protein-cou-pled receptors studied by mutational analysis of the m3 muscarinic receptor. EMBO J 1993, 12, 331-338.

274. Wieland, K.; Zuurmond, H. M.; Krasel, C.; Ijzer-man, A. P.; Lohse, M. J. Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor. Proc Natl Acad Sci U S A 1996, 93, 9276-9281.

275. Yao, B. B.; Hutchins, C. W.; Carr, T. L.; Cassar, S.; Masters, J. N.; Bennani, Y. L.; Esbenshade, T. A.; Hancock, A. A. Molecular modeling and pharmacological analysis of species-related histamine H(3) receptor heterogeneity. Neuro-pharmacology 2003, 44, 773-786.

276. Katritch, V.; Reynolds, K. A.; Cherezov, V.; Han-son, M. A.; Roth, C. B.; Yeager, M.; Abagyan, R. Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific con-formational changes. J Mol Recognit 2009, 22, 307-318.

277. Seifert, R.; Dove, S. Functional selectivity of GPCR ligand stereoisomers: new pharmaco-logical opportunities. Mol Pharmacol 2009, 75, 13-18.

278. Rosenbaum, D. M.; Cherezov, V.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Yao, X. J.; Weis, W. I.; Stevens, R. C.; Kobilka, B. K. GPCR engineering yields high-resolution structural insights into be-ta2-adrenergic receptor function. Science 2007, 318, 1266-1273.

279. Suryanarayana, S.; Daunt, D. A.; Von Zastrow, M.; Kobilka, B. K. A point mutation in the sev-enth hydrophobic domain of the alpha 2 adren-ergic receptor increases its affinity for a family of beta receptor antagonists. J Biol Chem 1991, 266, 15488-15492.

280. Ericksen, S. S.; Cummings, D. F.; Teer, M. E.; Amdani, S.; Schetz, J. A. Ring substituents on substituted benzamide ligands indirectly me-diate interactions with position 7.39 of trans-membrane helix 7 of the D4 dopamine recep-tor. J Pharmacol Exp Ther 2012, 342, 472-485.

281. Celanire, S.; Wijtmans, M.; Talaga, P.; Leurs, R.; de Esch, I. J. Keynote review: histamine H3 receptor antagonists reach out for the clinic. Drug Discov Today 2005, 10, 1613-1627.

282. Istyastono, E. P.; de Graaf, C.; de Esch, I. J.;

191

References

R R

Leurs, R. Molecular determinants of selective agonist and antagonist binding to the hista-mine H4 receptor. Curr Top Med Chem 2011, 11, 661-679.

283. Smits, R. A.; Leurs, R.; de Esch, I. J. Major ad-vances in the development of histamine H4 receptor ligands. Drug Discov Today 2009, 14, 745-753.

284. Shah, J. R.; Mosier, P. D.; Roth, B. L.; Kellogg, G. E.; Westkaemper, R. B. Synthesis, structure-af-finity relationships, and modeling of AMDA an-alogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem 2009, 17, 6496-6504.

285. Smits, R. A.; Lim, H. D.; van der Meer, T.; Kuhne, S.; Bessembinder, K.; Zuiderveld, O. P.; Wijt-mans, M.; de Esch, I. J.; Leurs, R. Ligand based design of novel histamine H(4) receptor antag-onists; fragment optimization and analysis of binding kinetics. Bioorg Med Chem Lett 2012, 22, 461-467.

286. Govoni, M.; Lim, H. D.; El-Atmioui, D.; Menge, W. M.; Timmerman, H.; Bakker, R. A.; Leurs, R.; De Esch, I. J. A chemical switch for the modu-lation of the functional activity of higher ho-mologues of histamine on the human histamine H3 receptor: effect of various substitutions at the primary amino function. J Med Chem 2006, 49, 2549-2557.

287. Lim, H. D.; van Rijn, R. M.; Ling, P.; Bakker, R. A.; Thurmond, R. L.; Leurs, R. Evaluation of his-tamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identifica-tion of 4-methylhistamine as the first potent and selective H4 receptor agonist. J Pharmacol Exp Ther 2005, 314, 1310-1321.

288. Granier, S.; Manglik, A.; Kruse, A. C.; Kobilka, T. S.; Thian, F. S.; Weis, W. I.; Kobilka, B. K. Struc-ture of the delta-opioid receptor bound to nal-trindole. Nature 2012, 485, 400-404.

289. Wu, H.; Wacker, D.; Mileni, M.; Katritch, V.; Han, G. W.; Vardy, E.; Liu, W.; Thompson, A. A.; Huang, X. P.; Carroll, F. I.; Mascarella, S. W.; Westkaemper, R. B.; Mosier, P. D.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the human kappa-opioid receptor in complex with JDTic. Nature 2012, 485, 327-332.

290. Manglik, A.; Kruse, A. C.; Kobilka, T. S.; Thian, F. S.; Mathiesen, J. M.; Sunahara, R. K.; Pardo, L.; Weis, W. I.; Kobilka, B. K.; Granier, S. Crystal structure of the micro-opioid receptor bound

to a morphinan antagonist. Nature 2012, 485, 321-326.

291. Poulain, R.; Horvath, D.; Bonnet, B.; Eckhoff, C.; Chapelain, B.; Bodinier, M. C.; Deprez, B. From hit to lead. Analyzing structure-profile relationships. J Med Chem 2001, 44, 3391-3401.

292. Selent, J.; Lopez, L.; Sanz, F.; Pastor, M. Multi-receptor binding profile of clozapine and olanzapine: a structural study based on the new beta2 adrenergic receptor template. ChemMedChem 2008, 3, 1194-1198.

293. Bolden, C.; Cusack, B.; Richelson, E. Antago-nism by antimuscarinic and neuroleptic com-pounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 1992, 260, 576-580.

294. Schotte, A.; Janssen, P. F.; Gommeren, W.; Luy-ten, W. H.; Van Gompel, P.; Lesage, A. S.; De Loore, K.; Leysen, J. E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychophar-macology 1996, 124, 57-73.

295. Lundstrom, K.; Turpin, M. P.; Large, C.; Rob-ertson, G.; Thomas, P.; Lewell, X. Q. Mapping of dopamine D3 receptor binding site by pharmacological characterization of mutants expressed in CHO cells with the Semliki For-est virus system. J Recept Signal Transduct Res 1998, 18, 133-150.

296. Singh, R.; Hurst, D. P.; Barnett-Norris, J.; Lynch, D. L.; Reggio, P. H.; Guarnieri, F. Acti-vation of the cannabinoid CB1 receptor may involve a W6 48/F3 36 rotamer toggle switch. J Pept Res 2002, 60, 357-370.

297. Schwartz, T. W.; Frimurer, T. M.; Holst, B.; Rosenkilde, M. M.; Elling, C. E. Molecular mechanism of 7TM receptor activation--a global toggle switch model. Annu Rev Pharma-col Toxicol 2006, 46, 481-519.

298. Holst, B.; Nygaard, R.; Valentin-Hansen, L.; Bach, A.; Engelstoft, M. S.; Petersen, P. S.; Frimurer, T. M.; Schwartz, T. W. A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seven-transmembrane re-ceptors. J Biol Chem 2010, 285, 3973-3985.

299. Sansuk, K.; Deupi, X.; Torrecillas, I. R.; Jongejan, A.; Nijmeijer, S.; Bakker, R. A.; Pardo, L.; Leurs, R. A structural insight into the reorientation of transmembrane domains 3 and 5 during family

192

References

R R

A G protein-coupled receptor activation. Mol Pharmacol 2011, 79, 262-269.

300. Shi, L.; Liapakis, G.; Xu, R.; Guarnieri, F.; Ball-esteros, J. A.; Javitch, J. A. Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem 2002, 277, 40989-40996.

301. Bakker, R. A.; Nicholas, M. W.; Smith, T. T.; Burstein, E. S.; Hacksell, U.; Timmerman, H.; Leurs, R.; Brann, M. R.; Weiner, D. M. In vitro pharmacology of clinically used central ner-vous system-active drugs as inverse H(1) re-ceptor agonists. J Pharmacol Exp Ther 2007, 322, 172-179.

302. Warne, T.; Moukhametzianov, R.; Baker, J. G.; Nehme, R.; Edwards, P. C.; Leslie, A. G.; Schertler, G. F.; Tate, C. G. The structural ba-sis for agonist and partial agonist action on a beta(1)-adrenergic receptor. Nature 2011, 469, 241-244.

303. Rasmussen, S. G.; Choi, H. J.; Fung, J. J.; Par-don, E.; Casarosa, P.; Chae, P. S.; Devree, B. T.; Rosenbaum, D. M.; Thian, F. S.; Kobilka, T. S.; Schnapp, A.; Konetzki, I.; Sunahara, R. K.; Gell-man, S. H.; Pautsch, A.; Steyaert, J.; Weis, W. I.; Kobilka, B. K. Structure of a nanobody-stabi-lized active state of the beta(2) adrenoceptor. Nature 2011, 469, 175-180.

304. Ishikawa, M.; Watanabe, T.; Kudo, T.; Yokoya-ma, F.; Yamauchi, M.; Kato, K.; Kakui, N.; Sato, Y. Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid ag-onists with a lipophilic side chain. J Med Chem 2010, 53, 6445-6456.

305. Lorenzi, S.; Mor, M.; Bordi, F.; Rivara, S.; Rivara, M.; Morini, G.; Bertoni, S.; Ballabeni, V.; Baro-celli, E.; Plazzi, P. V. Validation of a histamine H3 receptor model through structure-activity relationships for classical H3 antagonists. Bio-org Med Chem 2005, 13, 5647-5657.

306. May, L. T.; Leach, K.; Sexton, P. M.; Christopou-los, A. Allosteric modulation of G protein-cou-pled receptors. Annu Rev Pharmacol Toxicol 2007, 47, 1-51.

307. Bruysters, M.; Jongejan, A.; Gillard, M.; van de Manakker, F.; Bakker, R. A.; Chatelain, P.; Leurs, R. Pharmacological differences between human and guinea pig histamine H1 receptors: Asn84 (2.61) as key residue within an additional binding pocket in the H1 receptor. Mol Pharma-col 2005, 67, 1045-1052.

308. Simpson, M. M.; Ballesteros, J. A.; Chiappa, V.; Chen, J.; Suehiro, M.; Hartman, D. S.; Godel, T.; Snyder, L. A.; Sakmar, T. P.; Javitch, J. A. Dopa-mine D4/D2 receptor selectivity is determined by A divergent aromatic microdomain con-tained within the second, third, and seventh membrane-spanning segments. Mol Pharmacol 1999, 56, 1116-1126.

309. Peeters, M. C.; Wisse, L. E.; Dinaj, A.; Vroling, B.; Vriend, G.; Ijzerman, A. P. The role of the second and third extracellular loops of the ad-enosine A1 receptor in activation and allosteric modulation. Biochem Pharmacol 2012, 84, 76-87.

310. Wheatley, M.; Wootten, D.; Conner, M. T.; Simms, J.; Kendrick, R.; Logan, R. T.; Poyner, D. R.; Barwell, J. Lifting the lid on GPCRs: the role of extracellular loops. Br J Pharmacol 2012, 165, 1688-1703.

311. Peeters, M. C.; van Westen, G. J.; Li, Q.; AP, I. J. Importance of the extracellular loops in G pro-tein-coupled receptors for ligand recognition and receptor activation. Trends Pharmacol Sci 2011, 32, 35-42.

312. Lim, H. D.; Jongejan, A.; Bakker, R. A.; Haaks-ma, E.; de Esch, I. J.; Leurs, R. Phenylalanine 169 in the second extracellular loop of the hu-man histamine H4 receptor is responsible for the difference in agonist binding between hu-man and mouse H4 receptors. J Pharmacol Exp Ther 2008, 327, 88-96.

313. Shi, L.; Javitch, J. A. The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. Proc Natl Acad Sci U S A 2004, 101, 440-445.

314. Huang, X. P.; Prilla, S.; Mohr, K.; Ellis, J. Critical amino acid residues of the common allosteric site on the M2 muscarinic acetylcholine recep-tor: more similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type hexamethy-lene-bis-[dimethyl-(3-phthalimidopropyl)am-monium]dibromide. Mol Pharmacol 2005, 68, 769-778.

315. Krejci, A.; Tucek, S. Changes of cooperativity between N-methylscopolamine and allosteric modulators alcuronium and gallamine induced by mutations of external loops of muscarinic M-3 receptors. Mol Pharmacol 2001, 60, 761-767.

316. Scholten, D.; Canals, M.; Maussang, D.; Rou-

193

References

R R

men, L.; Smit, M.; Wijtmans, M.; de Graaf, C.; Vischer, H.; Leurs, R. Pharmacological Modu-lation of Chemokine Receptor Function. Br J Pharmacol 2012, 165, 1617-1643.

317. Kedzie, K. M.; Donello, J. E.; Krauss, H. A.; Re-gan, J. W.; Gil, D. W. A single amino-acid substi-tution in the EP2 prostaglandin receptor con-fers responsiveness to prostacyclin analogs. Mol Pharmacol 1998, 54, 584-590.

318. Mohr, K.; Trankle, C.; Kostenis, E.; Barocelli, E.; De Amici, M.; Holzgrabe, U. Rational design of dualsteric GPCR ligands: quests and promise. Br J Pharmacol 2010, 159, 997-1008.

319. Hoare, S. R.; Coldwell, M. C.; Armstrong, D.; Strange, P. G. Regulation of human D(1), d(2(long)), d(2(short)), D(3) and D(4) dopa-mine receptors by amiloride and amiloride an-alogues. Br J Pharmacol 2000, 130, 1045-1059.

320. Leppik, R. A.; Lazareno, S.; Mynett, A.; Birdsall, N. J. Characterization of the allosteric inter-actions between antagonists and amiloride analogues at the human alpha2A-adrenergic receptor. Mol Pharmacol 1998, 53, 916-925.

321. Steinfeld, T.; Hughes, A. D.; Klein, U.; Smith, J. A.; Mammen, M. THRX-198321 is a bifunctional muscarinic receptor antagonist and beta2-ad-renoceptor agonist (MABA) that binds in a bi-modal and multivalent manner. Mol Pharmacol 2011, 79, 389-399.

322. Im, W. B.; Chio, C. L.; Alberts, G. L.; Dinh, D. M. Positive allosteric modulator of the human 5-HT2C receptor. Mol Pharmacol 2003, 64, 78-84.

323. Birnkammer, T.; Spickenreither, A.; Brunskole, I.; Lopuch, M.; Kagermeier, N.; Bernhardt, G.; Dove, S.; Seifert, R.; Elz, S.; Buschauer, A. The bivalent ligand approach leads to highly potent and selective acylguanidine-type histamine H(2) receptor agonists. J Med Chem 2012, 55, 1147-1160.

324. Procopiou, P. A.; Browning, C.; Buckley, J. M.; Clark, K. L.; Fechner, L.; Gore, P. M.; Hancock, A. P.; Hodgson, S. T.; Holmes, D. S.; Kranz, M.; Looker, B. E.; Morriss, K. M.; Parton, D. L.; Rus-sell, L. J.; Slack, R. J.; Sollis, S. L.; Vile, S.; Watts, C. J. The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis. J Med Chem 2011, 54, 2183-2195.

325. Smits, R. A.; Lim, H. D.; Hanzer, A.; Zuiderveld,

O. P.; Guaita, E.; Adami, M.; Coruzzi, G.; Leurs, R.; de Esch, I. J. Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo. J Med Chem 2008, 51, 2457-2467.

326. Wang, T.; Duan, Y. Ligand entry and exit path-ways in the beta2-adrenergic receptor. J Mol Biol 2009, 392, 1102-1115.

327. Nijmeijer, S.; Engelhardt, H.; Schultes, S.; van de Stolpe, A. C.; Lusink, V.; de Graaf, C.; Wijt-mans, M.; Haaksma, E. E.; de Esch, I. J.; Stachur-ski, K.; Vischer, H. F.; Leurs, R. Design and phar-macological characterization of VUF14480, a covalent partial agonist that interacts with cysteine 98(3.36) of the human histamine H(4) receptor. Br J Pharmacol 2013, 170, 89-100.

328. Leurs, R.; Vischer, H. F.; Wijtmans, M.; de Esch, I. J. En route to new blockbuster anti-hista-mines: surveying the offspring of the expand-ing histamine receptor family. Trends Pharma-col Sci 2011, 32, 250-257.

329. Thurmond, R. L.; Gelfand, E. W.; Dunford, P. J. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 2008, 7, 41-53.

330. Schalon, C.; Surgand, J. S.; Kellenberger, E.; Rognan, D. A simple and fuzzy method to align and compare druggable ligand-binding sites. Proteins 2008, 71, 1755-1778.

331. Vassilatis, D. K.; Hohmann, J. G.; Zeng, H.; Li, F.; Ranchalis, J. E.; Mortrud, M. T.; Brown, A.; Rodriguez, S. S.; Weller, J. R.; Wright, A. C.; Bergmann, J. E.; Gaitanaris, G. A. The G pro-tein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci U S A 2003, 100, 4903-4908.

332. Mohr, K.; Schmitz, J.; Schrage, R.; Trankle, C.; Holzgrabe, U. Molecular alliance-from ortho-steric and allosteric ligands to dualsteric/bi-topic agonists at G protein coupled receptors. Angew Chem Int Ed Engl 2013, 52, 508-516.

333. Baker, J. G. The selectivity of beta-adrenocep-tor agonists at human beta1-, beta2- and be-ta3-adrenoceptors. Br J Pharmacol 2010, 160, 1048-1061.

334. Wijtmans, M.; de Graaf, C.; de Kloe, G.; Istyasto-no, E. P.; Smit, J.; Lim, H.; Boonnak, R.; Nijmei-jer, S.; Smits, R. A.; Jongejan, A.; Zuiderveld, O.; de Esch, I. J.; Leurs, R. Triazole ligands reveal distinct molecular features that induce hista-

194

References

R R

mine H4 receptor affinity and subtly govern H4/H3 subtype selectivity. J Med Chem 2011, 54, 1693-1703.

335. Stumpfe, D.; Bajorath, J. Exploring activity cliffs in medicinal chemistry. J Med Chem 2012, 55, 2932-2942.

336. Macarron, R. Critical review of the role of HTS in drug discovery. Drug Discov Today 2006, 11, 277-279.

337. Murray, C. W.; Verdonk, M. L.; Rees, D. C. Ex-periences in fragment-based drug discovery. Trends Pharmacol Sci 2012, 33, 224-232.

338. Mannhold, R.; Kubinyi, H.; Folkers, G.; Vaz, R.; Klabunde, T. Antitargets: prediction and pre-vention of drug side effects. John Wiley & Sons: 2008.

339. Rosenbaum, D. M.; Rasmussen, S. G.; Kobilka, B. K. The structure and function of G-pro-tein-coupled receptors. Nature 2009, 459, 356-363.

340. Topiol, S.; Sabio, M. X-ray structure break-throughs in the GPCR transmembrane region. Biochem. Pharmacol. 2009, 78, 11-20.

341. Leurs, R.; Church, M. K.; Taglialatela, M. H1-an-tihistamines: inverse agonism, anti-inflamma-tory actions and cardiac effects. Clin Exp Aller-gy 2002, 32, 489-498.

342. Clark, D. E.; Higgs, C.; Wren, S. P.; Dyke, H. J.; Wong, M.; Norman, D.; Lockey, P. M.; Roach, A. G. A virtual screening approach to finding nov-el and potent antagonists at the melanin-con-centrating hormone 1 receptor. J Med Chem 2004, 47, 3962-3971.

343. Rognan, D. Fragment-Based Approaches and Computer-Aided Drug Discovery. Top Curr Chem 2011, 1-22.

344. Overington, J. ChEMBL. An interview with John Overington, team leader, chemogenom-ics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI). Interview by Wendy A. Warr. J. Comput. Aided Mol. Des. 2009, 23, 195-198.

345. Korb, O.; Stutzle, T.; Exner, T. E. Empirical scoring functions for advanced protein-ligand docking with PLANTS. J Chem Inf Model 2009, 49, 84-96.

346. Ferrara, P.; Gohlke, H.; Price, D. J.; Klebe, G.; Brooks, C. L., 3rd. Assessing scoring functions for protein-ligand interactions. J Med Chem 2004, 47, 3032-3047.

347. Jain, A. N.; Nicholls, A. Recommendations for evaluation of computational methods. J Com-put Aided Mol Des 2008, 22, 133-139.

348. Verheij, M. H.; de Graaf, C.; de Kloe, G. E.; Nijmeijer, S.; Vischer, H. F.; Smits, R. A.; Zuid-erveld, O. P.; Hulscher, S.; Silvestri, L.; Thomp-son, A. J.; van Muijlwijk-Koezen, J. E.; Lummis, S. C.; Leurs, R.; de Esch, I. J. Fragment library screening reveals remarkable similarities be-tween the G protein-coupled receptor his-tamine H(4) and the ion channel serotonin 5-HT(3A). Bioorg. Medicinal Chem. Lett. 2011, 5460-5464.

349. Siegal, G.; Ab, E.; Schultz, J. Integration of fragment screening and library design. Drug Discov Today 2007, 12, 1032-1039.

350. Wawer, M.; Bajorath, J. Similarity-potency trees: a method to search for SAR information in compound data sets and derive SAR rules. J Chem Inf Model 2010, 50, 1395-1409.

351. Grant, J. A.; Gallardo, M. A.; Pickup, B. T. A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape. J. Comput. Chem. 1996, 17, 1653-1666.

352. Rognan, D. Docking Methods for Virtual Screening: Principles and Recent Advances. In Virtual Screening, Wiley-VCH Verlag GmbH & Co. KGaA: 2011; pp 153-176.

353. O'Boyle, N. M.; Liebeschuetz, J. W.; Cole, J. C. Testing assumptions and hypotheses for rescoring success in protein-ligand docking. J Chem Inf Model 2009, 49, 1871-1878.

354. Knox, A. J.; Meegan, M. J.; Sobolev, V.; Frost, D.; Zisterer, D. M.; Williams, D. C.; Lloyd, D. G. Target specific virtual screening: optimization of an estrogen receptor screening platform. J Med Chem 2007, 50, 5301-5310.

355. Steffen, A.; Kogej, T.; Tyrchan, C.; Engkvist, O. Comparison of molecular fingerprint methods on the basis of biological profile data. J Chem Inf Model 2009, 49, 338-347.

356. Fan, Y.; Lai, M. H.; Sullivan, K.; Popiolek, M.; Andree, T. H.; Dollings, P.; Pausch, M. H. The identification of neurotensin NTS1 receptor partial agonists through a ligand-based virtual screening approach. Bioorg. Medicinal Chem. Lett. 2008, 18, 5789-5791.

357. Gillespie, R. J.; Cliffe, I. A.; Dawson, C. E.; Dour-ish, C. T.; Gaur, S.; Jordan, A. M.; Knight, A. R.; Lerpiniere, J.; Misra, A.; Pratt, R. M.; Roffey, J.;

195

References

R R

Stratton, G. C.; Upton, R.; Weiss, S. M.; William-son, D. S. Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]py-rimidines and 6-arylpurines. Bioorg. Medicinal Chem. Lett. 2008, 18, 2924-2929.

358. Miller, D. C.; Klute, W.; Calabrese, A.; Brown, A. D. Optimising metabolic stability in lipophilic chemical space: the identification of a meta-bolically stable pyrazolopyrimidine CRF-1 re-ceptor antagonist. Bioorg. Medicinal Chem. Lett. 2009, 19, 6144-6147.

359. Venhorst, J.; Nunez, S.; Terpstra, J. W.; Kruse, C. G. Assessment of scaffold hopping efficien-cy by use of molecular interaction fingerprints. J Med Chem 2008, 51, 3222-3229.

360. Xu, J. A new approach to finding natural chem-ical structure classes. J Med Chem 2002, 45, 5311-5320.

361. Westly, E. Nothing to sneeze at. Nat Med 2010, 16, 1063-1065.

362. Wu, C. H.; Apweiler, R.; Bairoch, A.; Natale, D. A.; Barker, W. C.; Boeckmann, B.; Ferro, S.; Gasteiger, E.; Huang, H.; Lopez, R.; Magrane, M.; Martin, M. J.; Mazumder, R.; O'Donovan, C.; Redaschi, N.; Suzek, B. The Universal Pro-tein Resource (UniProt): an expanding uni-verse of protein information. Nucleic Acids Res. 2006, 34, D187-D191.

363. Violin, J. D.; Lefkowitz, R. J. Beta-arrestin-bi-ased ligands at seven-transmembrane recep-tors. Trends Pharmacol Sci 2007, 28, 416-422.

364. Calculator, 5.1.4; ChemAxon Kft.: Záhony u. 7, Building HX, 1031 Budapest, Hungary.

365. Sadowski, J.; Gasteiger, J.; Klebe, G. Compar-ison of automatic three-dimensional model builders using 639 X-ray structures. J Chem Inf Comput Sci 1994, 34, 1000-1008.

366. FILTER, version 2.1.1; OpenEye Scientific Soft-ware: Santa Fe, NM.

367. Swaminath, G.; Xiang, Y.; Lee, T. W.; Steenhuis, J.; Parnot, C.; Kobilka, B. K. Sequential binding of agonists to the beta2 adrenoceptor. Kinet-ic evidence for intermediate conformational states. J Biol Chem 2004, 279, 686-691.

368. Petrongolo, C.; Macchia, B.; Macchia, F.; Martinelli, A. Molecular orbital studies on the mechanism of drug-receptor interaction. 2. beta-Adrenergic drugs. An approach to explain the role of the aromatic moiety. J Med Chem 1977, 20, 1645-1653.

369. Reiter, E.; Ahn, S.; Shukla, A. K.; Lefkowitz, R. J. Molecular mechanism of beta-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol 2012, 52, 179-197.

370. van Linden, O. P.; Kooistra, A. J.; Leurs, R.; de Esch, I. J.; de Graaf, C. KLIFS: A knowl-edge-based structural database to navigate kinase-ligand interaction space. J Med Chem 2013.

371. Fukui, H.; Fujimoto, K.; Mizuguchi, H.; Saka-moto, K.; Horio, Y.; Takai, S.; Yamada, K.; Ito, S. Molecular cloning of the human histamine H1 receptor gene. Biochem. Biophys. Res. Commun. 1994, 201, 894-901.

372. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentra-tion of inhibitor which causes 50 per cent inhi-bition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.

373. Hopkins, A. L.; Groom, C. R. The druggable ge-nome. Nat Rev Drug Discov 2002, 1, 727-730.

374. Kooistra, A. J.; de Graaf, C.; Timmerman, H. The Receptor Concept in 3D: From Hypothesis and Metaphor to GPCR–Ligand Structures. Neuro-chem Res 2014, 1-12.

375. Kooistra, A. J.; Leurs, R.; de Esch, I. J.; de Graaf, C. From three-dimensional GPCR structure to rational ligand discovery. Adv Exp Med Biol 2014, 796, 129-157.

376. Congreve, M.; Dias, J. M.; Marshall, F. H. Struc-ture-based drug design for g protein-coupled receptors. Prog Med Chem 2014, 53, 1-63.

377. Vass, M.; Schmidt, E.; Horti, F.; Keseru, G. M. Virtual fragment screening on GPCRs: a case study on dopamine D3 and histamine H4 re-ceptors. Eur J Med Chem 2014, 77, 38-46.

378. Foloppe, N. The benefits of constructing leads from fragment hits. Future Med Chem 2011, 3, 1111-1115.

379. Shoichet, B. K.; Kobilka, B. K. Structure-based drug screening for G-protein-coupled recep-tors. Trends Pharmacol Sci 2012, 33, 268-272.

380. Kenakin, T.; Miller, L. J. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selec-tivity on new drug discovery. Pharmacol Rev 2010, 62, 265-304.

381. Nakamura, S.; Itabashi, T.; Ogawa, D.; Okada, T. Common and distinct mechanisms of activa-tion of rhodopsin and other G protein-coupled receptors. Sci Rep 2013, 3, 1844.

196

References

R R

382. Nygaard, R.; Zou, Y.; Dror, R. O.; Mildorf, T. J.; Arlow, D. H.; Manglik, A.; Pan, A. C.; Liu, C. W.; Fung, J. J.; Bokoch, M. P.; Thian, F. S.; Kobilka, T. S.; Shaw, D. E.; Mueller, L.; Prosser, R. S.; Ko-bilka, B. K. The dynamic process of beta(2)-ad-renergic receptor activation. Cell 2013, 152, 532-542.

383. Tehan, B. G.; Bortolato, A.; Blaney, F. E.; Weir, M. P.; Mason, J. S. Unifying Family A GPCR Theories of Activation. Pharmacol Ther 2014, 143, 51-60.

384. Kobilka, B. The structural basis of G-pro-tein-coupled receptor signaling (Nobel Lec-ture). Angew Chem Int Ed Engl 2013, 52, 6380-6388.

385. Pipeline Pilot, 6.1.5; Accelrys Software Inc.: 5005 Waterridge Vista Dr, San Diego, CA 92121, United States.

386. Rasmussen, S. G.; Choi, H. J.; Rosenbaum, D. M.; Kobilka, T. S.; Thian, F. S.; Edwards, P. C.; Burghammer, M.; Ratnala, V. R.; Sanishvili, R.; Fischetti, R. F.; Schertler, G. F.; Weis, W. I.; Kobilka, B. K. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 2007, 450, 383-387.

387. Warne, T.; Serrano-Vega, M. J.; Baker, J. G.; Moukhametzianov, R.; Edwards, P. C.; Hen-derson, R.; Leslie, A. G.; Tate, C. G.; Schertler, G. F. Structure of a beta1-adrenergic G-pro-tein-coupled receptor. Nature 2008, 454, 486-491.

388. Rosenbaum, D. M.; Zhang, C.; Lyons, J. A.; Holl, R.; Aragao, D.; Arlow, D. H.; Rasmussen, S. G.; Choi, H. J.; Devree, B. T.; Sunahara, R. K.; Chae, P. S.; Gellman, S. H.; Dror, R. O.; Shaw, D. E.; Weis, W. I.; Caffrey, M.; Gmeiner, P.; Kobilka, B. K. Structure and function of an irreversible agonist-beta(2) adrenoceptor complex. Nature 2011, 469, 236-240.

389. Kooistra, A. J.; Kuhne, S.; de Esch, I. J.; Leurs, R.; de Graaf, C. A structural chemogenomics analysis of aminergic GPCRs: lessons for his-tamine receptor ligand design. Br J Pharmacol 2013, 170, 101-126.

390. Moukhametzianov, R.; Warne, T.; Edwards, P. C.; Serrano-Vega, M. J.; Leslie, A. G.; Tate, C. G.; Schertler, G. F. Two distinct conformations of helix 6 observed in antagonist-bound struc-tures of a beta1-adrenergic receptor. Proc Natl Acad Sci U S A 2011, 108, 8228-8232.

391. Zou, Y.; Weis, W. I.; Kobilka, B. K. N-terminal T4

lysozyme fusion facilitates crystallization of a G protein coupled receptor. PloS one 2012, 7, e46039.

392. Christopher, J.; Brown, J.; Dore, A.; Errey, J.; Koglin, M.; Marshall, F. H.; Myszka, D.; Rich, R. L.; Tate, C. G.; Tehan, B.; Warne, T.; Congreve, M. Biophysical fragment screening of the beta1-adrenergic receptor: Identification of high affinity aryl piperazine leads using struc-ture-based drug design. J Med Chem 2013.

393. Huang, J.; Chen, S.; Zhang, J. J.; Huang, X. Y. Crystal structure of oligomeric beta-adrener-gic G protein-coupled receptors in ligand-free basal state. Nat Struct Mol Biol 2013.

394. Weichert, D.; Kruse, A. C.; Manglik, A.; Hill-er, C.; Zhang, C.; Hubner, H.; Kobilka, B. K.; Gmeiner, P. Covalent agonists for studying G protein-coupled receptor activation. Proc Natl Acad Sci U S A 2014, 111, 10744-10748.

395. Weiss, D. R.; Ahn, S.; Sassano, M. F.; Kleist, A.; Zhu, X.; Strachan, R.; Roth, B. L.; Lefkowitz, R. J.; Shoichet, B. K. Conformation guides molec-ular efficacy in docking screens of activated beta-2 adrenergic G protein coupled receptor. ACS Chem Biol 2013, 8, 1018-1026.

396. Kellenberger, E.; Rodrigo, J.; Muller, P.; Rog-nan, D. Comparative evaluation of eight dock-ing tools for docking and virtual screening ac-curacy. Proteins 2004, 57, 225-242.

397. Rodriguez, D.; Brea, J.; Loza, M. I.; Carlsson, J. Structure-Based Discovery of Selective Se-rotonin 5-HT1B Receptor Ligands. Structure 2014, 22, 1140-1151.

398. Barber, R.; Kelly, L. A.; McGuire, R. F.; Butcher, R. W. Distortion of cyclic AMP responses to catecholamine due to destruction of the hor-mone. J Cyclic Nucleotide Res 1977, 3, 249-261.

399. Soriano-Ursua, M. A.; McNaught-Flores, D. A.; Nieto-Alamilla, G.; Segura-Cabrera, A.; Cor-rea-Basurto, J.; Arias-Montano, J. A.; Trujil-lo-Ferrara, J. G. Cell-based and in-silico studies on the high intrinsic activity of two boron-con-taining salbutamol derivatives at the human beta(2)-adrenoceptor. Bioorg Med Chem 2012, 20, 933-941.

400. Hattori, K.; Orita, M.; Toda, S.; Imanishi, M.; Itou, S.; Nakajima, Y.; Tanabe, D.; Washizuka, K.; Araki, T.; Sakurai, M.; Matsui, S.; Imamura, E.; Ueshima, K.; Yamamoto, T.; Yamamoto, N.; Ishikawa, H.; Nakano, K.; Unami, N.; Hamada, K.; Matsumura, Y.; Takamura, F. Discovery of

197

References

R R

highly potent and selective biphenylacylsul-fonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6. Bioorg Med Chem Lett 2009, 19, 4679-4683.

401. Ochoa, R.; Davies, M.; Papadatos, G.; Atkin-son, F.; Overington, J. P. myChEMBL: a virtu-al machine implementation of open data and cheminformatics tools. Bioinformatics 2014, 30, 298-300.

402. Blum, L. C.; van Deursen, R.; Reymond, J. L. Visualisation and subsets of the chemical uni-verse database GDB-13 for virtual screening. J Comput Aided Mol Des 2011, 25, 637-647.

403. Zhu, X.-l.; Cai, H.-y.; Xu, Z.-j.; Wang, Y.; Wang, H.-y.; Zhang, A.; Zhu, W.-l. Classification of 5-HT1A receptor agonists and antagonists us-ing GA-SVM method. Acta Pharmacol Sin 2011, 32, 1424-1430.

404. Reynolds, K. A.; Katritch, V.; Abagyan, R. Iden-tifying conformational changes of the beta(2) adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators. J Comput Aided Mol Des 2009, 23, 273-288.

405. Kalani, M. Y.; Vaidehi, N.; Hall, S. E.; Trabanino, R. J.; Freddolino, P. L.; Kalani, M. A.; Floriano, W. B.; Kam, V. W.; Goddard, W. A., 3rd. The predicted 3D structure of the human D2 do-pamine receptor and the binding site and bind-ing affinities for agonists and antagonists. Proc Natl Acad Sci U S A 2004, 101, 3815-3820.

406. Xu, F.; Wu, H.; Katritch, V.; Han, G. W.; Jacob-son, K. A.; Gao, Z. G.; Cherezov, V.; Stevens, R. C. Structure of an agonist-bound human A2A adenosine receptor. Science 2011, 332, 322-327.

407. van der Westhuizen, E. T.; Breton, B.; Chris-topoulos, A.; Bouvier, M. Quantification of ligand bias for clinically relevant beta2-adren-ergic receptor ligands: implications for drug taxonomy. Mol Pharmacol 2014, 85, 492-509.

408. Sato, T.; Kobayashi, H.; Nagao, T.; Kurose, H. Ser203 as well as Ser204 and Ser207 in fifth transmembrane domain of the human be-ta2-adrenoceptor contributes to agonist bind-ing and receptor activation. Br J Pharmacol 1999, 128, 272-274.

409. Kikkawa, H.; Kurose, H.; Isogaya, M.; Sato, Y.; Nagao, T. Differential contribution of two ser-

ine residues of wild type and constitutively active beta2-adrenoceptors to the interaction with beta2-selective agonists. Br J Pharmacol 1997, 121, 1059-1064.

410. Jianyi, Y.; Yang, Z. GPCR-EXP: a database for experimentally solved GPCR structures. http://zhanglab.ccmb.med.umich.edu/GPCR-EXP/ (2014-03-30).

411. White, J. F.; Noinaj, N.; Shibata, Y.; Love, J.; Kloss, B.; Xu, F.; Gvozdenovic-Jeremic, J.; Shah, P.; Shiloach, J.; Tate, C. G.; Grisshammer, R. Structure of the agonist-bound neurotensin receptor. Nature 2012, 490, 508-513.

412. Vilar, S.; Karpiak, J.; Berk, B.; Costanzi, S. In silico analysis of the binding of agonists and blockers to the beta2-adrenergic receptor. J Mol Graph Model 2011, 29, 809-817.

413. Strader, C. D.; Candelore, M. R.; Hill, W. S.; Sigal, I. S.; Dixon, R. A. Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. J Biol Chem 1989, 264, 13572-13578.

414. Verlinde, C. L.; Hol, W. G. Structure-based drug design: progress, results and challenges. Struc-ture 1994, 2, 577-587.

415. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a ge-netic algorithm for flexible docking. J Mol Biol 1997, 267, 727-748.

416. Barril, X.; Morley, S. D. Unveiling the full poten-tial of flexible receptor docking using multiple crystallographic structures. J Med Chem 2005, 48, 4432-4443.

417. Katritch, V.; Rueda, M.; Abagyan, R. Li-gand-guided receptor optimization. Methods Mol Biol 2012, 857, 189-205.

418. Meng, X. Y.; Zhang, H. X.; Mezei, M.; Cui, M. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des 2011, 7, 146-157.

419. Rognan, D.; Desaphy, J. Molecular Interaction Fingerprints. In Scaffold Hopping in Medicinal Chemistry, Wiley-VCH Verlag GmbH & Co. KGaA: 2013; pp 215-230.

420. Molecular Operating Environment (MOE), 2012.10; Chemical Computing Group Inc.: 1010 Sherbooke St. West, Suite #910, Montreal, QC H3A 2R7, Canada, 2012.

421. Carey, F. A.; Sundberg, R. J. Advanced Organic Chemistry: Part A: Structure and Mechanisms. Springer: 2007.

198

References

R R

422. Durrant, J. D.; de Oliveira, C. A.; McCammon, J. A. POVME: an algorithm for measuring bind-ing-pocket volumes. J Mol Graph Model 2011, 29, 773-776.

423. Baker, J. G. The selectivity of beta-adrenocep-tor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 2005, 144, 317-322.

424. CORINA, 3.4.9; The 3D structure generator CORINA is available from Molecular Networks GmbH,: Molecular Networks GmbH, Erlangen, Germany.

425. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved pro-tein-ligand docking using GOLD. Proteins 2003, 52, 609-623.

426. McMartin, C.; Bohacek, R. S. QXP: powerful, rapid computer algorithms for structure-based drug design. J Comput Aided Mol Des 1997, 11, 333-344.

427. OEChem TK, 1.7.2.4; OpenEye Scientific Soft-ware Inc.: 9 Bisbee Court, Suite D, Santa Fe, NM 87508, United States.

428. Andrews, S. P.; Brown, G. A.; Christopher, J. A. Structure-Based and Fragment-Based GPCR Drug Discovery. ChemMedChem 2013.

429. Warne, T.; Tate, C. G. The importance of inter-actions with helix 5 in determining the effica-cy of beta-adrenoceptor ligands. Biochem Soc Trans 2013, 41, 159-165.

430. Casella, I.; Ambrosio, C.; Gro, M. C.; Molinari, P.; Costa, T. Divergent agonist selectivity in activating beta1- and beta2-adrenoceptors for G-protein and arrestin coupling. Biochem J 2011, 438, 191-202.

431. Selvam, B.; Wereszczynski, J.; Tikhonova, I. G. Comparison of dynamics of extracellular ac-cesses to the beta(1) and beta(2) adrenocep-tors binding sites uncovers the potential of ki-netic basis of antagonist selectivity. Chem Biol Drug Des 2012, 80, 215-226.

432. Drake, M. T.; Violin, J. D.; Whalen, E. J.; Wisler, J. W.; Shenoy, S. K.; Lefkowitz, R. J. Beta-ar-restin-biased agonism at the beta2-adrenergic receptor. J Biol Chem 2008, 283, 5669-5676.

433. Kahsai, A. W.; Xiao, K.; Rajagopal, S.; Ahn, S.; Shukla, A. K.; Sun, J.; Oas, T. G.; Lefkowitz, R. J. Multiple ligand-specific conformations of the beta2-adrenergic receptor. Nat Chem Biol 2011, 7, 692-700.

434. Kaya, A. I.; Onaran, H. O.; Ozcan, G.; Ambrosio,

C.; Costa, T.; Balli, S.; Ugur, O. Cell contact-de-pendent functional selectivity of beta2-adren-ergic receptor ligands in stimulating cAMP ac-cumulation and extracellular signal-regulated kinase phosphorylation. J Biol Chem 2012, 287, 6362-6374.

435. Kim, I. M.; Tilley, D. G.; Chen, J.; Salazar, N. C.; Whalen, E. J.; Violin, J. D.; Rockman, H. A. Be-ta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A 2008, 105, 14555-14560.

436. Rajagopal, S.; Ahn, S.; Rominger, D. H.; Gow-en-MacDonald, W.; Lam, C. M.; Dewire, S. M.; Violin, J. D.; Lefkowitz, R. J. Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol 2011, 80, 367-377.

437. Maack, C.; Bohm, M.; Vlaskin, L.; Dabew, E.; Lorenz, K.; Schafers, H. J.; Lohse, M. J.; Engel-hardt, S. Partial agonist activity of bucindolol is dependent on the activation state of the human beta1-adrenergic receptor. Circulation 2003, 108, 348-353.

438. Sheftel, S.; Muratore, K. E.; Black, M.; Costan-zi, S. Graph analysis of β 2 adrenergic receptor structures: a “social network” of GPCR resi-dues. 2013.

439. Weis, W. I.; Kobilka, B. K. Structural insights into G-protein-coupled receptor activation. Curr Opin Struct Biol 2008, 18, 734-740.

440. Strader, C. D.; Candelore, M. R.; Hill, W. S.; Dixon, R. A.; Sigal, I. S. A single amino acid sub-stitution in the beta-adrenergic receptor pro-motes partial agonist activity from antagonists. J Biol Chem 1989, 264, 16470-16477.

441. Rajagopal, S.; Rajagopal, K.; Lefkowitz, R. J. Teaching old receptors new tricks: biasing sev-en-transmembrane receptors. Nat Rev Drug Discov 2010, 9, 373-386.

442. Galandrin, S.; Bouvier, M. Distinct signaling profiles of beta1 and beta2 adrenergic re-ceptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 2006, 70, 1575-1584.

443. Gregory, K. J.; Sexton, P. M.; Tobin, A. B.; Chris-topoulos, A. Stimulus bias provides evidence for conformational constraints in the structure of a G protein-coupled receptor. J Biol Chem 2012, 287, 37066-37077.

444. Audet, M.; Bouvier, M. Insights into signaling

199

References

R R

from the beta2-adrenergic receptor structure. Nat Chem Biol 2008, 4, 397-403.

445. Costanzi, S. Modeling G protein-coupled re-ceptors in complex with biased agonists. Trends Pharmacol Sci 2014.

446. Sullivan, R. J.; Pantanowitz, L.; Casper, C.; Steb-bing, J.; Dezube, B. J. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sar-coma-associated herpesvirus disease: Kapo-si sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis 2008, 47, 1209-1215.

447. Carbone, A.; Vaccher, E.; Gloghini, A.; Panta-nowitz, L.; Abayomi, A.; de Paoli, P.; Franceschi, S. Diagnosis and management of lymphomas and other cancers in HIV-infected patients. Nat Rev Clin Oncol 2014, 11, 223-238.

448. Letang, E.; Lewis, J. J.; Bower, M.; Mosam, A.; Borok, M.; Campbell, T. B.; Naniche, D.; New-som-Davis, T.; Shaik, F.; Fiorillo, S.; Miro, J. M.; Schellenberg, D.; Easterbrook, P. J. Immune re-constitution inflammatory syndrome associat-ed with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. Aids 2013, 27, 1603-1613.

449. Nguyen, H. Q.; Magaret, A. S.; Kitahata, M. M.; Van Rompaey, S. E.; Wald, A.; Casper, C. Per-sistent Kaposi sarcoma in the era of highly ac-tive antiretroviral therapy: characterizing the predictors of clinical response. Aids 2008, 22, 937-945.

450. Chang, Y.; Cesarman, E.; Pessin, M. S.; Lee, F.; Culpepper, J.; Knowles, D. M.; Moore, P. S. Identification of herpesvirus-like DNA se-quences in AIDS-associated Kaposi's sarcoma. Science 1994, 266, 1865-1869.

451. Dittmer, D. P. Transcription profile of Kapo-si's sarcoma-associated herpesvirus in prima-ry Kaposi's sarcoma lesions as determined by real-time PCR arrays. Cancer Res 2003, 63, 2010-2015.

452. Guo, H. G.; Sadowska, M.; Reid, W.; Tschachler, E.; Hayward, G.; Reitz, M. Kaposi's sarcoma-like tumors in a human herpesvirus 8 ORF74 trans-genic mouse. J Virol 2003, 77, 2631-2639.

453. Yang, T. Y.; Chen, S. C.; Leach, M. W.; Manfra, D.; Homey, B.; Wiekowski, M.; Sullivan, L.; Jenh, C. H.; Narula, S. K.; Chensue, S. W.; Lira, S. A. Transgenic expression of the chemokine re-ceptor encoded by human herpesvirus 8 induc-es an angioproliferative disease resembling Ka-

posi's sarcoma. J Exp Med 2000, 191, 445-454.454. Montaner, S.; Kufareva, I.; Abagyan, R.; Gut-

kind, J. S. Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases. Annu Rev Pharmacol Toxicol 2013, 53, 331-354.

455. Arvanitakis, L.; Geras-Raaka, E.; Varma, A.; Gershengorn, M. C.; Cesarman, E. Human her-pesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell pro-liferation. Nature 1997, 385, 347-350.

456. Rosenkilde, M. M.; Kledal, T. N.; Brauner-Os-borne, H.; Schwartz, T. W. Agonists and inverse agonists for the herpesvirus 8-encoded con-stitutively active seven-transmembrane onco-gene product, ORF-74. J Biol Chem 1999, 274, 956-961.

457. Holst, P. J.; Rosenkilde, M. M.; Manfra, D.; Chen, S. C.; Wiekowski, M. T.; Holst, B.; Ci-fire, F.; Lipp, M.; Schwartz, T. W.; Lira, S. A. Tumorigenesis induced by the HHV8-encoded chemokine receptor requires ligand modula-tion of high constitutive activity. J Clin Invest 2001, 108, 1789-1796.

458. Feng, H.; Sun, Z.; Farzan, M. R.; Feng, P. Sul-fotyrosines of the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor pro-mote tumorigenesis through autocrine activa-tion. J Virol 2010, 84, 3351-3361.

459. Pati, S.; Cavrois, M.; Guo, H. G.; Foulke, J. S., Jr.; Kim, J.; Feldman, R. A.; Reitz, M. Activa-tion of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi's sarcoma patho-genesis. J Virol 2001, 75, 8660-8673.

460. Sodhi, A.; Montaner, S.; Gutkind, J. S. Viral hi-jacking of G-protein-coupled-receptor signal-ling networks. Nat Rev Mol Cell Biol 2004, 5, 998-1012.

461. Montaner, S.; Sodhi, A.; Ramsdell, A. K.; Martin, D.; Hu, J.; Sawai, E. T.; Gutkind, J. S. The Ka-posi's sarcoma-associated herpesvirus G pro-tein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. Cancer Res 2006, 66, 168-174.

462. Pease, J. E.; Horuk, R. Chemokine Receptors in Allergy, Inflammation, and Infectious Disease. 2014.

463. Solari, R.; Pease, J. E.; Begg, M. "Chemokine receptors as therapeutic targets: Why aren't there more drugs?". Eur J Pharmacol 2014.

200

References

R R

464. Schmidt, D.; Bernat, V.; Brox, R.; Tschammer, N.; Kolb, P. Identifying Modulators of CXC Re-ceptors 3 and 4 with Tailored Selectivity Using Multi-Target Docking. ACS Chem Biol 2014.

465. Kooistra, A. J.; Roumen, L.; Leurs, R.; de Esch, I. J.; de Graaf, C. From heptahelical bundle to hits from the Haystack: structure-based virtual screening for GPCR ligands. Methods Enzymol 2013, 522, 279-336.

466. Berman, H. M.; Westbrook, J.; Feng, Z.; Gillil-and, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res 2000, 28, 235-242.

467. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeabili-ty. J Pharmacol Toxicol Methods 2000, 44, 235-249.

468. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A 'rule of three' for fragment-based lead discov-ery? Drug Discov Today 2003, 8, 876-877.

469. Hulshof, J. W.; Casarosa, P.; Menge, W. M.; Kuusisto, L. M.; van der Goot, H.; Smit, M. J.; de Esch, I. J.; Leurs, R. Synthesis and structure-ac-tivity relationship of the first nonpeptidergic inverse agonists for the human cytomegalovi-rus encoded chemokine receptor US28. J Med Chem 2005, 48, 6461-6471.

470. Hulshof, J. W.; Vischer, H. F.; Verheij, M. H.; Fratantoni, S. A.; Smit, M. J.; de Esch, I. J.; Leurs, R. Synthesis and pharmacological char-acterization of novel inverse agonists acting on the viral-encoded chemokine receptor US28. Bioorg Med Chem 2006, 14, 7213-7230.

471. Vischer, H. F.; Hulshof, J. W.; Hulscher, S.; Fratantoni, S. A.; Verheij, M. H.; Victorina, J.; Smit, M. J.; de Esch, I. J.; Leurs, R. Identification of novel allosteric nonpeptidergic inhibitors of the human cytomegalovirus-encoded chemok-ine receptor US28. Bioorg Med Chem 2010, 18, 675-688.

472. Saita, Y.; Kodama, E.; Orita, M.; Kondo, M.; Mi-yazaki, T.; Sudo, K.; Kajiwara, K.; Matsuoka, M.; Shimizu, Y. Structural Basis for the Interaction of CCR5 with a Small Molecule, Functionally Selective CCR5 Agonist. J Immunol 2006, 177, 3116-3122.

473. Rosenkilde, M. M.; Andersen, M. B.; Nygaard, R.; Frimurer, T. M.; Schwartz, T. W. Activation of the CXCR3 Chemokine Receptor through Anchoring of a Small Molecule Chelator Ligand between TM-III, -IV, and -VI. Mol Pharmacol

2007, 71, 930-941.474. Casarosa, P.; Menge, W. M.; Minisini, R.; Otto,

C.; van Heteren, J.; Jongejan, A.; Timmerman, H.; Moepps, B.; Kirchhoff, F.; Mertens, T.; Smit, M. J.; Leurs, R. Identification of the first non-peptidergic inverse agonist for a constitutively active viral-encoded G protein-coupled recep-tor. J Biol Chem 2003, 278, 5172-5178.

475. de Mendonca, F. L.; da Fonseca, P. C.; Phillips, R. M.; Saldanha, J. W.; Williams, T. J.; Pease, J. E. Site-directed mutagenesis of CC chemok-ine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. J Biol Chem 2005, 280, 4808-4816.

476. Wise, E. L.; Duchesnes, C.; da Fonseca, P. C.; Allen, R. A.; Williams, T. J.; Pease, J. E. Small molecule receptor agonists and antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation. J Biol Chem 2007, 282, 27935-27943.

477. Moriconi, A.; Cesta, M. C.; Cervellera, M. N.; Aramini, A.; Coniglio, S.; Colagioia, S.; Beccari, A. R.; Bizzarri, C.; Cavicchia, M. R.; Locati, M.; Galliera, E.; Di Benedetto, P.; Vigilante, P.; Ber-tini, R.; Allegretti, M. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem 2007, 50, 3984-4002.

478. Vaidehi, N.; Schlyer, S.; Trabanino, R. J.; Floria-no, W. B.; Abrol, R.; Sharma, S.; Kochanny, M.; Koovakat, S.; Dunning, L.; Liang, M.; Fox, J. M.; de Mendonca, F. L.; Pease, J. E.; Goddard, W. A., 3rd; Horuk, R. Predictions of CCR1 chemo-kine receptor structure and BX 471 antagonist binding followed by experimental validation. J Biol Chem 2006, 281, 27613-27620.

479. Berkhout, T. A.; Blaney, F. E.; Bridges, A. M.; Cooper, D. G.; Forbes, I. T.; Gribble, A. D.; Groot, P. H.; Hardy, A.; Ife, R. J.; Kaur, R.; Moores, K. E.; Shillito, H.; Willetts, J.; Wither-ington, J. CCR2: characterization of the antag-onist binding site from a combined receptor modeling/mutagenesis approach. J Med Chem 2003, 46, 4070-4086.

480. Kondru, R.; Zhang, J.; Ji, C.; Mirzadegan, T.; Rotstein, D.; Sankuratri, S.; Dioszegi, M. Mo-lecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 2008, 73, 789-800.

481. Jensen, P. C.; Nygaard, R.; Thiele, S.; Elder, A.; Zhu, G.; Kolbeck, R.; Ghosh, S.; Schwartz, T. W.;

201

References

R R

Rosenkilde, M. M. Molecular interaction of a potent nonpeptide agonist with the chemokine receptor CCR8. Mol Pharmacol 2007, 72, 327-340.

482. Wong, R. S.; Bodart, V.; Metz, M.; Labrecque, J.; Bridger, G.; Fricker, S. P. Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol Pharmacol 2008, 74, 1485-1495.

483. de Kruijf, P.; Lim, H. D.; Roumen, L.; Renjaan, V. A.; Zhao, J.; Webb, M. L.; Auld, D. S.; Wijk-mans, J. C.; Zaman, G. J.; Smit, M. J.; de Graaf, C.; Leurs, R. Identification of a novel allosteric binding site in the CXCR2 chemokine receptor. Mol Pharmacol 2011, 80, 1108-1118.

484. Scholten, D. J.; Roumen, L.; Wijtmans, M.; Ver-kade-Vreeker, M. C.; Custers, H.; Lai, M.; de Hooge, D.; Canals, M.; de Esch, I. J.; Smit, M. J.; de Graaf, C.; Leurs, R. Identification of over-lapping but differential binding sites for the high-affinity CXCR3 antagonists NBI-74330 and VUF11211. Mol Pharmacol 2014, 85, 116-126.

485. Roumen, L.; Scholten, D. J.; de Kruijf, P.; de Esch, I. J.; Leurs, R.; de Graaf, C. C(X)CR in sil-ico: Computer-aided prediction of chemokine receptor-ligand interactions. Drug Discov Today Technol 2012, 9, e281-291.

486. Vischer, H. F.; Siderius, M.; Leurs, R.; Smit, M. J. Herpesvirus-encoded GPCRs: neglected play-ers in inflammatory and proliferative diseases? Nat Rev Drug Discov 2014, 13, 123-139.

487. Kufareva, I.; Abagyan, R.; Handel, T. M. Role of 3D Structures in Understanding, Predicting, and Designing Molecular Interactions in the Chemokine Receptor Family. 2014.

488. Costanzi, S. Modeling G protein-coupled re-ceptors and their interactions with ligands. Curr Opin Struct Biol 2013, 23, 185-190.

489. Benedetti, P.; Mannhold, R.; Cruciani, G.; Pas-tor, M. GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND). J Med Chem 2002, 45, 1577-1584.

490. Singh, S. Chemistry, design, and structure-ac-tivity relationship of cocaine antagonists. Chem Rev 2000, 100, 925-1024.

491. Dittrich, H. C. COR-ART: A Multicenter, Ran-domized, Double-Blind, Placebo-Controlled Dose Modification Study To Evaluate Single

Oral Doses Of GBR-12909 For Conversion Of Subjects With Atrial Fibrillation Or Flutter Of Recent Onset To Normal Sinus Rhythm. In American Heart Association meeting, Dallas, Texas, 2013.

492. Diamond, S.; Schenbaum, H. Flunarizine, a cal-cium channel blocker, in the prophylactic treat-ment of migraine. Headache 1983, 23, 39-42.

493. Thiele, S.; Rosenkilde, M. M. Interaction of chemokines with their receptors--from ini-tial chemokine binding to receptor activating steps. Curr Med Chem 2014, 21, 3594-3614.

494. Ho, H. H.; Du, D.; Gershengorn, M. C. The N terminus of Kaposi's sarcoma-associated her-pesvirus G protein-coupled receptor is neces-sary for high affinity chemokine binding but not for constitutive activity. J Biol Chem 1999, 274, 31327-31332.

495. Blanpain, C.; Doranz, B. J.; Bondue, A.; Gov-aerts, C.; De Leener, A.; Vassart, G.; Doms, R. W.; Proudfoot, A.; Parmentier, M. The core do-main of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J Biol Chem 2003, 278, 5179-5187.

496. Allegretti, M.; Bertini, R.; Bizzarri, C.; Beccari, A.; Mantovani, A.; Locati, M. Allosteric inhibi-tors of chemoattractant receptors: opportuni-ties and pitfalls. Trends Pharmacol Sci 2008, 29, 280-286.

497. Rummel, P. C.; Arfelt, K. N.; Baumann, L.; Jen-kins, T. J.; Thiele, S.; Luttichau, H. R.; Johnsen, A.; Pease, J.; Ghosh, S.; Kolbeck, R.; Rosenkilde, M. M. Molecular requirements for inhibition of the chemokine receptor CCR8--probe-de-pendent allosteric interactions. Br J Pharmacol 2012, 167, 1206-1217.

498. Ho, H. H.; Ganeshalingam, N.; Rosen-house-Dantsker, A.; Osman, R.; Gershengorn, M. C. Charged residues at the intracellular boundary of transmembrane helices 2 and 3 independently affect constitutive activity of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. J Biol Chem 2001, 276, 1376-1382.

499. Rummel, P. C.; Thiele, S.; Hansen, L. S.; Pe-tersen, T. P.; Sparre-Ulrich, A. H.; Ulven, T.; Rosenkilde, M. M. Extracellular disulfide bridg-es serve different purposes in two homologous chemokine receptors, CCR1 and CCR5. Mol Pharmacol 2013, 84, 335-345.

202

References

R R

500. Daiyasu, H.; Nemoto, W.; Toh, H. Evolution-ary Analysis of Functional Divergence among Chemokine Receptors, Decoy Receptors, and Viral Receptors. Front Microbiol 2012, 3, 264.

501. Simossis, V. A.; Heringa, J. PRALINE: a multiple sequence alignment toolbox that integrates homology-extended and secondary struc-ture information. Nucleic Acids Res 2005, 33, W289-294.

502. Moon, M. J.; Kim, H. Y.; Park, S.; Kim, D. K.; Cho, E. B.; Park, C. R.; You, D. J.; Hwang, J. I.; Kim, K.; Choe, H.; Seong, J. Y. Evolutionarily conserved residues at glucagon-like peptide-1 (GLP-1) re-ceptor core confer ligand-induced receptor activation. J Biol Chem 2012, 287, 3873-3884.

503. Perola, E.; Walters, W. P.; Charifson, P. S. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance. Proteins 2004, 56, 235-249.

504. Verzijl, D.; Storelli, S.; Scholten, D. J.; Bosch, L.; Reinhart, T. A.; Streblow, D. N.; Tensen, C. P.; Fitzsimons, C. P.; Zaman, G. J.; Pease, J. E.; de Esch, I. J.; Smit, M. J.; Leurs, R. Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at pri-mate and rodent CXCR3 chemokine receptors. J Pharmacol Exp Ther 2008, 325, 544-555.

505. Gruijthuijsen, Y. K.; Casarosa, P.; Kaptein, S. J.; Broers, J. L.; Leurs, R.; Bruggeman, C. A.; Smit, M. J.; Vink, C. The rat cytomegalovirus R33-encoded G protein-coupled receptor sig-nals in a constitutive fashion. J Virol 2002, 76, 1328-1338.

506. Bennett, G. L.; Horuk, R. Iodination of chemo-kines for use in receptor binding analysis. Meth-ods Enzymol 1997, 288, 134-148.

507. Phillips, J. C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R. D.; Kale, L.; Schulten, K. Scalable molecular dynamics with NAMD. J Comp Chem 2005, 26, 1781-1802.

508. Klauda, J. B.; Venable, R. M.; Freites, J. A.; O'Connor, J. W.; Tobias, D. J.; Mondrag-on-Ramirez, C.; Vorobyov, I.; MacKerell, A. D., Jr.; Pastor, R. W. Update of the CHARMM all-atom additive force field for lipids: valida-tion on six lipid types. J Phys Chem B 2010, 114, 7830-7843.

509. Jorgensen, W. L. Comparison of simple po-tential functions for simulating liquid water. J Chem Phys 1983, 79, 926-935.

510. Best, R. B.; Zhu, X.; Shim, J.; Lopes, P. E.; Mittal, J.; Feig, M.; Mackerell, A. D., Jr. Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone phi, psi and side-chain chi(1) and chi(2) dihedral angles. J Chem Theory Comput 2012, 8, 3257-3273.

511. Vanommeslaeghe, K.; Raman, E. P.; MacKerell, A. D., Jr. Automation of the CHARMM General Force Field (CGenFF) II: assignment of bonded parameters and partial atomic charges. J Chem Inf Model 2012, 52, 3155-3168.

512. Jansen, C.; Wang, H.; Kooistra, A. J.; de Graaf, C.; Orrling, K. M.; Tenor, H.; Seebeck, T.; Bailey, D.; de Esch, I. J.; Ke, H.; Leurs, R. Discovery of novel Trypanosoma brucei phosphodiesterase B1 inhibitors by virtual screening against the unliganded TbrPDEB1 crystal structure. J Med Chem 2013, 56, 2087-2096.

513. Maeda, S.; Schertler, G. F. Production of GPCR and GPCR complexes for structure determina-tion. Curr Opin Struct Biol 2013, 23, 381-392.

514. Christopoulos, A. Advances in GPCR Allostery: From Function to Structure. Mol Pharmacol 2014.

515. Mujic-Delic, A.; de Wit, R. H.; Verkaar, F.; Smit, M. J. GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics. Trends Pharmacol Sci 2014, 35, 247-255.

516. Stevens, C. W. G Protein-Coupled Receptors: Research and Methods in the Post-Genomic Era. In G Protein-Coupled Receptor Genetics, Springer: 2014; pp 3-22.

517. Giguere, P. M.; Kroeze, W. K.; Roth, B. L. Tuning up the right signal: chemical and genetic ap-proaches to study GPCR functions. Curr Opin Cell Biol 2014, 27, 51-55.

518. Congreve, M.; Langmead, C.; Marshall, F. H. The use of GPCR structures in drug design. Adv Pharmacol 2011, 62, 1-36.

519. Swinney, D. C.; Beavis, P.; Chuang, K. T.; Zheng, Y.; Lee, I.; Gee, P.; Deval, J.; Rotstein, D. M.; Di-oszegi, M.; Ravendran, P.; Zhang, J.; Sankuratri, S.; Kondru, R.; Vauquelin, G. A study into the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands. Br J Pharma-col 2014.

520. Guo, D.; Venhorst, S. N.; Massink, A.; van Veld-hoven, J. P.; Vauquelin, G.; AP, I. J.; Heitman, L. H. Molecular mechanism of allosteric modula-

203

References

R R

tion at GPCRs: insight from a binding kinetics study at the human A adenosine receptor. Br J Pharmacol 2014.

521. Beuming, T.; Che, Y.; Abel, R.; Kim, B.; Shanmu-gasundaram, V.; Sherman, W. Thermodynamic analysis of water molecules at the surface of proteins and applications to binding site pre-diction and characterization. Proteins 2012, 80, 871-883.

522. Toll, L.; Pajak, K.; Plazinska, A.; Jozwiak, K.; Jimenez, L.; Kozocas, J. A.; Tanga, M. J.; Bupp, J. E.; Wainer, I. W. Thermodynamics and docking of agonists to the beta(2)-adrenoceptor deter-mined using [(3)H](R,R')-4-methoxyfenoterol as the marker ligand. Mol Pharmacol 2012, 81, 846-854.

523. Peters, J. U. Polypharmacology - foe or friend? J Med Chem 2013, 56, 8955-8971.

524. Tautermann, C. S.; Kiechle, T.; Seeliger, D.; Diehl, S.; Wex, E.; Banholzer, R.; Gantner, F.; Pieper, M. P.; Casarosa, P. Molecular basis for the long duration of action and kinetic selectiv-ity of tiotropium for the muscarinic M3 recep-tor. J Med Chem 2013, 56, 8746-8756.

525. Brewerton, S. C. The use of protein-ligand in-teraction fingerprints in docking. Curr Opin Drug Discov Devel 2008, 11, 356-364.

526. Sotriffer, C. A.; Sanschagrin, P.; Matter, H.; Klebe, G. SFCscore: scoring functions for af-finity prediction of protein-ligand complexes. Proteins 2008, 73, 395-419.

527. Zilian, D.; Sotriffer, C. A. SFCscore(RF): a random forest-based scoring function for im-proved affinity prediction of protein-ligand complexes. J Chem Inf Model 2013, 53, 1923-1933.

528. Civelli, O.; Reinscheid, R. K.; Zhang, Y.; Wang, Z.; Fredriksson, R.; Schioth, H. B. G pro-tein-coupled receptor deorphanizations. Annu Rev Pharmacol Toxicol 2013, 53, 127-146.

529. Ballester, P. J.; Schreyer, A.; Blundell, T. L. Does a More Precise Chemical Description of Pro-tein–Ligand Complexes Lead to More Accurate Prediction of Binding Affinity? J Chem Inf Mod-el 2014, 54, 944-955.

530. Ballester, P. J. Machine learning scoring func-tions based on random forest and support vec-tor regression. In Pattern Recognition in Bioin-formatics, Springer Berlin Heidelberg: 2012; pp 14-25.

531. Li, H.; Leung, K.-S.; Wong, M.-H.; Ballester, P. J.

Substituting random forest for multiple linear regression improves binding affinity prediction of scoring functions: Cyscore as a case study. BMC Bioinformatics 2014, 15, 291.

532. Gabel, J.; Desaphy, J.; Rognan, D. Beware of machine learning-based scoring functions - On the danger of developing black boxes. J Chem Inf Model 2014.

533. Chupakhin, V.; Marcou, G.; Baskin, I.; Varnek, A.; Rognan, D. Predicting ligand binding modes from neural networks trained on protein-ligand interaction fingerprints. J Chem Inf Model 2013, 53, 763-772.

534. Hansson, T.; Marelius, J.; Aqvist, J. Ligand bind-ing affinity prediction by linear interaction en-ergy methods. J Comput Aided Mol Des 1998, 12, 27-35.

535. Aqvist, J.; Medina, C.; Samuelsson, J. E. A new method for predicting binding affinity in com-puter-aided drug design. Protein Eng 1994, 7, 385-391.

536. Åqvist, J.; Warshel, A. Molecular recognition in the catalytic action of metallo-enzymes. In Principles of Molecular Recognition, Springer: 1993; pp 108-136.

537. Lauro, G.; Ferruz, N.; Fulle, S.; Harvey, M. J.; Finn, P. W.; De Fabritiis, G. Reranking docking poses using molecular simulations and approx-imate free energy methods. J Chem Inf Model 2014, 54, 2185-2189.

538. Boukharta, L.; Gutierrez-de-Teran, H.; Aqvist, J. Computational prediction of alanine scan-ning and ligand binding energetics in G-protein coupled receptors. PLoS Comput Biol 2014, 10, e1003585.

539. Hayik, S. A.; Dunbrack, R., Jr.; Merz, K. M., Jr. A Mixed QM/MM Scoring Function to Predict Protein-Ligand Binding Affinity. J Chem Theory Comput 2010, 6, 3079-3091.

540. Jansen, C.; Kooistra, A. J.; de Esch, I. J. P.; Leurs, R.; de Graaf, C. PDEStrIAn PDE Struc-ture and ligand Interaction Annotated data-base. in preparation 2014.

541. Kellenberger, E.; Muller, P.; Schalon, C.; Bret, G.; Foata, N.; Rognan, D. sc-PDB: an Annotat-ed Database of Druggable Binding Sites from the Protein Data Bank. J Chem Inf Model 2006, 46, 717-727.

542. Desaphy, J.; Rognan, D. sc-PDB-Frag: a data-base of protein-ligand interaction patterns for Bioisosteric replacements. J Chem Inf Model

204

References

R R

2014, 54, 1908-1918.543. Meslamani, J.; Rognan, D.; Kellenberger, E. sc-

PDB: a database for identifying variations and multiplicity of 'druggable' binding sites in pro-teins. Bioinformatics 2011, 27, 1324-1326.

544. Rognan, D. Proteome-scale docking: myth and reality. Drug Discov Today Technol 2013, 10, e403-409.

545. Brylinski, M.; Skolnick, J. Comprehensive struc-tural and functional characterization of the hu-man kinome by protein structure modeling and ligand virtual screening. J Chem Inf Model 2010, 50, 1839-1854.

546. Shonberg, J.; Lopez, L.; Scammells, P. J.; Chris-topoulos, A.; Capuano, B.; Lane, J. R. Biased Agonism at G Protein-Coupled Receptors: The Promise and the Challenges-A Medicinal Chemistry Perspective. Med Res Rev 2014.

547. Park, J. H.; Scheerer, P.; Hofmann, K. P.; Choe, H. W.; Ernst, O. P. Crystal structure of the li-gand-free G-protein-coupled receptor opsin. Nature 2008, 454, 183-187.

548. Lebon, G.; Warne, T.; Edwards, P. C.; Bennett, K.; Langmead, C. J.; Leslie, A. G.; Tate, C. G. Agonist-bound adenosine A2A receptor struc-tures reveal common features of GPCR activa-tion. Nature 2011, 474, 521-525.

549. Lebon, G.; Warne, T.; Tate, C. G. Agonist-bound structures of G protein-coupled receptors. Curr Opin Struct Biol 2012, 22, 482-490.

550. Violin, J. D.; Crombie, A. L.; Soergel, D. G.; Lark, M. W. Biased ligands at G-protein-cou-pled receptors: promise and progress. Trends Pharmacol Sci 2014, 35, 308-316.

551. DeWire, S. M.; Violin, J. D. Biased ligands for better cardiovascular drugs: dissecting G-pro-tein-coupled receptor pharmacology. Circ Res 2011, 109, 205-216.

552. Nijmeijer, S.; Vischer, H. F.; Sirci, F.; Schultes, S.; Engelhardt, H.; de Graaf, C.; Rosethorne, E. M.; Charlton, S. J.; Leurs, R. Detailed analysis of biased histamine H(4) receptor signalling by JNJ 7777120 analogues. Br J Pharmacol 2013, 170, 78-88.

553. Allen, J. A.; Yost, J. M.; Setola, V.; Chen, X.; Sas-sano, M. F.; Chen, M.; Peterson, S.; Yadav, P. N.; Huang, X. P.; Feng, B.; Jensen, N. H.; Che, X.; Bai, X.; Frye, S. V.; Wetsel, W. C.; Caron, M. G.; Javitch, J. A.; Roth, B. L.; Jin, J. Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential

for antipsychotic efficacy. Proc Natl Acad Sci U S A 2011, 108, 18488-18493.

554. Valant, C.; May, L. T.; Aurelio, L.; Chuo, C. H.; White, P. J.; Baltos, J. A.; Sexton, P. M.; Scammells, P. J.; Christopoulos, A. Separation of on-target efficacy from adverse effects through rational design of a bitopic adenos-ine receptor agonist. Proc Natl Acad Sci U S A 2014, 111, 4614-4619.

555. Keov, P.; Sexton, P. M.; Christopoulos, A. Al-losteric modulation of G protein-coupled re-ceptors: a pharmacological perspective. Neu-ropharmacology 2011, 60, 24-35.

556. Salchow, K.; Bond, M. E.; Evans, S. C.; Press, N. J.; Charlton, S. J.; Hunt, P. A.; Bradley, M. E. A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Br J Phar-macol 2010, 159, 1429-1439.

557. Gonzalez, A.; Cordomi, A.; Matsoukas, M.; Zachmann, J.; Pardo, L. Modeling of G pro-tein-coupled receptors using crystal struc-tures: from monomers to signaling complexes. Adv Exp Med Biol 2014, 796, 15-33.

558. Johnston, J. M.; Wang, H.; Provasi, D.; Filizola, M. Assessing the relative stability of dimer in-terfaces in g protein-coupled receptors. PLoS Comput Biol 2012, 8, e1002649.

559. Taylor, C. M.; Barda, Y.; Kisselev, O. G.; Mar-shall, G. R. Modulating G-protein coupled re-ceptor/G-protein signal transduction by small molecules suggested by virtual screening. J Med Chem 2008, 51, 5297-5303.

560. Lane, J. R.; Chubukov, P.; Liu, W.; Canals, M.; Cherezov, V.; Abagyan, R.; Stevens, R. C.; Ka-tritch, V. Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors. Mol Pharmacol 2013, 84, 794-807.

561. Dror, R. O.; Green, H. F.; Valant, C.; Borhani, D. W.; Valcourt, J. R.; Pan, A. C.; Arlow, D. H.; Canals, M.; Lane, J. R.; Rahmani, R.; Baell, J. B.; Sexton, P. M.; Christopoulos, A.; Shaw, D. E. Structural basis for modulation of a G-pro-tein-coupled receptor by allosteric drugs. Na-ture 2013, 503, 295-299.

562. Valant, C.; Robert Lane, J.; Sexton, P. M.; Chris-topoulos, A. The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-cou-pled receptors. Annu Rev Pharmacol Toxicol 2012, 52, 153-178.

563. Chen, D.; Ranganathan, A.; AP, I. J.; Siegal, G.;

205

References

R R

Carlsson, J. Complementarity between in silico and biophysical screening approaches in frag-ment-based lead discovery against the A(2A) adenosine receptor. J Chem Inf Model 2013, 53, 2701-2714.

564. Bai, Q.; Shi, D.; Zhang, Y.; Liu, H.; Yao, X. Ex-ploration of the antagonist CP-376395 escape pathway for the corticotropin-releasing factor receptor 1 by random acceleration molecular dynamics simulations. Mol Biosyst 2014.

565. Aristotelous, T.; Ahn, S.; Shukla, A. K.; Gawron, S.; Sassano, M. F.; Kahsai, A. W.; Wingler, L. M.; Zhu, X.; Tripathi-Shukla, P.; Huang, X. P.; Riley, J.; Besnard, J.; Read, K. D.; Roth, B. L.; Gilbert, I. H.; Hopkins, A. L.; Lefkowitz, R. J.; Navratilo-va, I. Discovery of beta2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor. ACS Med Chem Lett 2013, 4, 1005-1010.

566. Andaloussi, M.; Lim, H. D.; van der Meer, T.; Sijm, M.; Poulie, C. B.; de Esch, I. J.; Leurs, R.; Smits, R. A. A novel series of histamine H4 receptor antagonists based on the pyr-ido[3,2-d]pyrimidine scaffold: comparison of hERG binding and target residence time with PF-3893787. Bioorg Med Chem Lett 2013, 23, 2663-2670.

567. Kikkawa, H.; Isogaya, M.; Nagao, T.; Kurose, H. The role of the seventh transmembrane region in high affinity binding of a beta 2-selective ag-onist TA-2005. Mol Pharmacol 1998, 53, 128-134.

568. Mason, J. S.; Bortolato, A.; Weiss, D. R.; De-florian, F.; Tehan, B.; Marshall, F. H. High end GPCR design: crafted ligand design and drug-gability analysis using protein structure, lipo-philic hotspots and explicit water networks. In Silico Pharmacol 2013, 1, 23.

569. Andrews, S. P.; Mason, J. S.; Hurrell, E.; Con-greve, M. Structure-based drug design of chromone antagonists of the adenosine A 2A receptor. Med Chem Commun 2014.

570. Bortolato, A.; Tehan, B. G.; Bodnarchuk, M. S.; Essex, J. W.; Mason, J. S. Water network per-turbation in ligand binding: adenosine A(2A) antagonists as a case study. J Chem Inf Model 2013, 53, 1700-1713.

571. Reddy, A. S.; Zhang, S. Polypharmacology: drug discovery for the future. Expert Rev Clin Phar-macol 2013, 6, 41-47.

572. Knight, Z. A.; Lin, H.; Shokat, K. M. Targeting

the cancer kinome through polypharmacology. Nat Rev Cancer 2010, 10, 130-137.

573. Peters, J.-U. Polypharmacology in drug discov-ery. John Wiley and Sons: 2012.

574. Dar, A. C.; Das, T. K.; Shokat, K. M.; Cagan, R. L. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Na-ture 2012, 486, 80-84.

575. Bell, J. K.; McQueen, D. S.; Rees, J. L. Involve-ment of histamine H4 and H1 receptors in scratching induced by histamine receptor ago-nists in Balb C mice. Br J Pharmacol 2004, 142, 374-380.

576. Chapin, M. J.; Belen, L.; Whitlock, A.; Wijkmans, J.; van de Meer, T.; Andaloussi, M.; Smits, R. A.; de Esch, I.; Leurs, R. The third generation of antihistamines: Assessment of Histamine H1/H4 Receptor Antagonists in a Murine Model of Allergic Conjunctivitis. Invest Ophthalmol Vis Sci 2014, 55, 2482.

577. McLeod, R. L.; Mingo, G. G.; Herczku, C.; De-Gennaro-Culver, F.; Kreutner, W.; Egan, R. W.; Hey, J. A. Combined histamine H1 and H3 re-ceptor blockade produces nasal decongestion in an experimental model of nasal congestion. Am J Rhinol 1999, 13, 391-399.

578. Petrov, K. G.; Zhang, Y.-M.; Carter, M.; Cock-erill, G. S.; Dickerson, S.; Gauthier, C. A.; Guo, Y.; Mook Jr, R. A.; Rusnak, D. W.; Walker, A. L.; Wood, E. R.; Lackey, K. E. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase in-hibition in the 6-furanylquinazoline series. Bio-org Med Chem Lett 2006, 16, 4686-4691.

579. Morphy, R. Selectively Nonselective Kinase Inhibition: Striking the Right Balance. J Med Chem 2009, 53, 1413-1437.

580. Uitdehaag, J. C.; de Roos, J. A.; van Doornma-len, A. M.; Prinsen, M. B.; de Man, J.; Tanizawa, Y.; Kawase, Y.; Yoshino, K.; Buijsman, R. C.; Zaman, G. J. Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. PloS one 2014, 9, e92146.

581. Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008, 4, 682-690.

582. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares,

206

References

R R

G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26, 127–132.

583. Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011, 29, 1046-1051.

584. Barretina, J.; Caponigro, G.; Stransky, N.; Ven-katesan, K.; Margolin, A. A.; Kim, S.; Wilson, C. J.; Lehar, J.; Kryukov, G. V.; Sonkin, D.; Reddy, A.; Liu, M.; Murray, L.; Berger, M. F.; Monah-an, J. E.; Morais, P.; Meltzer, J.; Korejwa, A.; Jane-Valbuena, J.; Mapa, F. A.; Thibault, J.; Bric-Furlong, E.; Raman, P.; Shipway, A.; En-gels, I. H.; Cheng, J.; Yu, G. K.; Yu, J.; Aspesi, P., Jr.; de Silva, M.; Jagtap, K.; Jones, M. D.; Wang, L.; Hatton, C.; Palescandolo, E.; Gupta, S.; Ma-han, S.; Sougnez, C.; Onofrio, R. C.; Liefeld, T.; MacConaill, L.; Winckler, W.; Reich, M.; Li, N.; Mesirov, J. P.; Gabriel, S. B.; Getz, G.; Ardlie, K.; Chan, V.; Myer, V. E.; Weber, B. L.; Porter, J.; Warmuth, M.; Finan, P.; Harris, J. L.; Meyerson, M.; Golub, T. R.; Morrissey, M. P.; Sellers, W. R.; Schlegel, R.; Garraway, L. A. The Cancer Cell Line Encyclopedia enables predictive model-ling of anticancer drug sensitivity. Nature 2012, 483, 603-607.

585. Garnett, M. J.; Edelman, E. J.; Heidorn, S. J.; Greenman, C. D.; Dastur, A.; Lau, K. W.; Greninger, P.; Thompson, I. R.; Luo, X.; Soares, J.; Liu, Q.; Iorio, F.; Surdez, D.; Chen, L.; Mila-no, R. J.; Bignell, G. R.; Tam, A. T.; Davies, H.; Stevenson, J. A.; Barthorpe, S.; Lutz, S. R.; Kogera, F.; Lawrence, K.; McLaren-Douglas, A.; Mitropoulos, X.; Mironenko, T.; Thi, H.; Richard-son, L.; Zhou, W.; Jewitt, F.; Zhang, T.; O'Brien, P.; Boisvert, J. L.; Price, S.; Hur, W.; Yang, W.; Deng, X.; Butler, A.; Choi, H. G.; Chang, J. W.; Baselga, J.; Stamenkovic, I.; Engelman, J. A.; Sharma, S. V.; Delattre, O.; Saez-Rodriguez, J.; Gray, N. S.; Settleman, J.; Futreal, P. A.; Haber, D. A.; Stratton, M. R.; Ramaswamy, S.; McDer-mott, U.; Benes, C. H. Systematic identification of genomic markers of drug sensitivity in can-cer cells. Nature 2012, 483, 570-575.

586. van Westen, G. J.; Wegner, J. K.; Geluykens, P.; Kwanten, L.; Vereycken, I.; Peeters, A.; Ijzerman, A. P.; van Vlijmen, H. W.; Bender, A. Which compound to select in lead optimiza-

tion? Prospectively validated proteochemo-metric models guide preclinical development. PloS one 2011, 6, e27518.

207

References

R R